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ABSTRACT
MICRO-PHYSIOLOGICAL MODELS TO MIMIC MUCOSAL BARRIER
COMPLEXITY OF THE HUMAN INTESTINE IN VITRO
September 2020
ABHINAV SHARMA
B.E., BABASAHEB AMBEDKAR MARATHWADA UNIVERSITY
M.Tech., INDIAN INSTITUTE OF TECHNOLOGY GUWAHATI
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Neil S. Forbes and Dr. Jungwoo Lee

The mucosal barrier in the intestine is vital to maintain selective absorption of
nutrients while protecting internal tissues and maintaining symbiotic relationship with
luminal microbiota. This bio-barrier consists of a cellular epithelial barrier and an acellular
mucus barrier. Secreted mucus regulates barrier function via in situ biochemical and
biophysical interaction with luminal content that continually evolves during digestion and
absorption. Increasing evidence suggests that a mucus barrier is indispensable to maintain
dynamic homeostasis of the gastrointestinal tract. However, the importance of mucus
barrier has been largely underrated for in vitro mucosal tissue modeling. The major gap is
the lack of experimental material (i.e. functional mucins) and platforms to integrate a
relevant thickness of mucus layer with an epithelium under physiological conditions.
Here we report our progress on developing human-relevant models of the mucosal
barrier in physiological settings by using natural mucins derived from a porcine small
intestine (PSI). To overcome limited availability of functional mucus, we first developed a
simple and scalable protocol for natural mucus extraction by directly solubilizing a
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relatively sterile inner mucus layer from PSI that is readily accessible. Subsequently,
functional separation of mucin proteins was performed by exploiting pH-dependent
reversible sol-gel transition. Under optimized alkaline condition (0.01M NaOH), the
mucus layer was selectively solubilized from the mucosal surface with a 72% yield (1275
mg/m PSI). The extracted and purified natural mucins retained essential biophysical and
biochemical characteristics. The in vitro mucus barrier model enabled us to discover ionic
(Ca2+) environment dependent mucus barrier and its transport properties.
The mucus barrier was successfully integrated with human epithelial cell layer (HT29), which allowed the studies of bi-directional crosstalk between luminal content and
tissue immune cells through a physiologically relevant mucosal interface. The applied
mucus barrier did not cause any cytotoxic or immunogenic effects to human intestinal and
immune cells. As expected, mucus prevents the transmigration of probiotic bacteria
VSL#3. In the absence of mucus, these bacteria caused epithelial damage, immune cell
differentiation and induced production of pro-inflammatory cytokines IL-8 and TNF-α.
The most intriguing result from these studies was that mucus increased the transmigration
of pathogenic Salmonella. Similar to the transmigration of probiotic bacteria, breach of the
mucosal barrier by Salmonella induced production of IL-8 and TNF-α. The importance of
bacterial motility was confirmed by showing that Salmonella with a knockout that prevents
flagella formation does not penetrate the barrier. Co-cultures of VSL#3 and Salmonella in
the mucosal barrier platform demonstrated the differences in epithelial and immune cell
responses under symbiosis or dysbiosis like conditions.
Taking bioengineering approaches, we have developed mucosal barrier models of
intestines. Established models represent cellular and extracellular complexities in a

vii

controlled and accessible manner. We envision that in vitro mucosal barrier models will
serve as an enabling tool for understanding basic biology and disease progression in the
intestines. Technologies, methods, and protocols developed here lay the foundation for
future clinical applications and personalized medicine.

GRAPHICAL ABSTRACT

viii

TABLE OF CONTENTS
Page
ACKNOWLEDGMENTS ...................................................................................................v
ABSTRACT....................................................................................................................... vi
GRAPHICAL ABSTRACT ............................................................................................. viii
LIST OF FIGURES ......................................................................................................... xiii
ADDITIONAL FIGURES .................................................................................................xv
CHAPTER
1.

INTRODUCTION ...................................................................................................1

2.

DEVELOPMENT OF A SCALABLE METHOD FOR MUCUS EXTRACTION
AND IN VITRO RECONSTITUTION OF AN INTESTINAL
MUCUS LAYER .....................................................................................................9
2.1 Introduction ........................................................................................................9
2.2 Results ..............................................................................................................13
2.2.1 Extraction of Natural Mucus ...................................................................13
2.2.2 Reconstituted PSIM Preserves Reversible pH Dependence ...................15
2.2.3 Barrier Function of PSIM is pH Dependent ...........................................16
2.2.4 Calcium Regulates PSIM at Neutral pH .................................................18
2.2.5 Calcium Controls the Thickness and Porosity of the Mucus Barrier......19
2.3 Discussion ........................................................................................................21
2.4 Materials and Methods .....................................................................................33
2.4.1 Natural mucin extraction from a porcine small intestine ........................33
2.4.2 Histological sectioning of the intestinal tissues ......................................34
2.4.3 Biophysical characterizations of the reconstituted mucus ......................35
2.4.4 Bacterial cell culture ...............................................................................36
2.4.5 Two-dimensional bacterial motility assay in PSIM on a glass slide ......36
2.4.6 Three-dimensional bacterial diffusion assay through PSIM in
transwell inserts ......................................................................................36
2.4.7 Fixation and cryo-sectioning of PSIM layers on transwell
membranes ..............................................................................................37

ix

2.4.8 Lectin staining for visualization of PSIM aggregates .............................38
2.4.9 Pore size distribution...............................................................................38
2.4.10 Fluorescent imaging and area overlap analysis ....................................39
2.4.11 Statistical analysis .................................................................................39
3.

MODEL OF INTESTINAL MUCOSA TO QUANTIFY THE ROLE OF MUCUS
AND EPITHELIAL BARRIER IN REGULATING THE HOST INNATE
IMMUNE RESPONSES TO PROBIOTIC AND
PATHOGENIC BACTERIA .................................................................................40
3.1 Introduction ......................................................................................................40
3.2 Results ..............................................................................................................44
3.2.1 PSIM formed a gel layer on top of epithelial cells without affecting
cell viability ............................................................................................44
3.2.2 PSIM is not immunogenic to epithelial or immune cells ........................45
3.2.3 Immunological responses from epithelial and immune cells are
stimulant dependent ................................................................................45
3.2.4 A PSIM gel layer prevents LPS induced immunogenic responses .........47
3.2.5 A PSIM gel layer is a barrier to migration of live probiotic bacteria .....48
3.2.6 PSIM gel layer enhances the transmigration of Salmonella ...................49
3.3 Discussion ........................................................................................................50
3.4 Materials and Methods .....................................................................................54
3.4.1 Human cell culture ..................................................................................54
3.4.2 PSIM extraction and purification ............................................................55
3.4.3 Bacteria culture .......................................................................................56
3.4.4 Epithelial cell seeding in transwell inserts ..............................................58
3.4.5 Mucus layer formation and cytotoxicity of PSIM on epithelial cells .....58
3.4.6 Immunological response of epithelial and immune cells to PSIM .........60
3.4.7 Direct stimulation of HT-29 and THP-1 monocultures ..........................61
3.4.8 Construction of in vitro mucosal lining model .......................................61
3.4.9 LPS interaction with in vitro mucosal lining model ...............................62
3.4.10 VSL#3 interaction with in vitro mucosal lining model ........................62
3.4.11 Salmonella interaction with in vitro mucosal lining model ..................63
3.4.12 Bacterial motility analysis.....................................................................63
3.4.13 Cryopreservation, histological sectioning, and
immunofluorescence staining ...............................................................64
3.4.14 Statistical analysis .................................................................................65

x

4.

APPLICATION OF INTESTINAL MUCOSA MODEL TO INVESTIGATE THE

EFFECT OF PROBIOTICS ON PATHOGENIC SALMONELLA INFECTION ...........75
4.1 Introduction ......................................................................................................75
4.2 Results ..............................................................................................................81
4.2.1 VSL#3 suppresses the growth of Salmonella in co-culture ....................81
4.2.2 Mucus gel matrix using PSIM match the colonic mucus layer
in vivo .....................................................................................................82
4.2.3 Presence of VSL#3 alters the host immune responses to
S. typhimurium ........................................................................................83
4.2.4 More S. typhimurium cross the epithelial layer in presence of the
mucus gel matrix .....................................................................................84
4.2.5 Epithelial and immune cell responses vary depending on the
bacterial stimuli .......................................................................................85
4.3 Discussion ........................................................................................................86
4.4 Materials and Methods .....................................................................................91
4.4.1 Mammalian cell culture ..........................................................................91
4.4.2 Solubilized PSIM preparation .................................................................91
4.4.3 VSL#3 and S. typhimurium bacteria culture ............................................92
4.4.4 HT-29 cell seeding and culture in transwells ..........................................93
4.4.5 Mucus gel matrix formation on HT-29 cell surface and mucosal
barrier platform setup ..............................................................................94
4.4.6 Stimulation of HT-29 and THP-1 monocultures with VSL#3 and
S. typhimurium ........................................................................................94
4.4.7 VSL#3 interaction with in vitro mucosal lining model ...........................95
4.4.8 S. typhimurium interaction with mucosal barrier model .........................95
4.4.9 VSL#3 and S. typhimurium coculture interaction with mucosal
barrier model ...........................................................................................96
4.4.10 Epithelial and immune cell responses vary depending on the
bacterial stimuli .................................................................................96
4.4.11 Mammalian cell culture ........................................................................98

5.

FUTURE APPLICATIONS AND CONCLUSION ............................................105
5.1 Development of a probiotic encapsulation and delivery vehicle
using PSIM.....................................................................................................105
5.2 Creation of a two-layer mucus barrier relevant to the large intestine mucus
barrier .............................................................................................................109
5.3 Microfluidic platform for dynamic mucus barrier formation using PSIM ....120

xi

5.4 ‘Intestine mucosal barrier on a chip’ for real time host-microbe interaction
........................................................................................................................103
5.5 Incorporation of primary gut organoids and immune cells for personalized
medicine .........................................................................................................132
5.6 Overall conclusion .........................................................................................135
BIBLIOGRAPHY ............................................................................................................142

xii

LIST OF FIGURES
Figure

Page

2.1

Extraction of porcine small intestine mucus (PSIM) ............................................25

2.2

Response of PSIM to pH........................................................................................26

2.3

Barrier function of PSIM ......................................................................................28

2.4

Calcium regulates the physical properties of PSIM ...............................................29

2.5

Calcium controls the thickness of the mucus barrier ............................................30

2.6

Calcium controls the porosity of the mucus barrier ...............................................31

2.7

Role of calcium as a regulator of molecular transport ..........................................32

3.1

Biocompatibility of epithelial and mucus gel layers formed on a
transwell membrane ..............................................................................................67

3.2

Immunological response of epithelial and immune cells to PSIM .......................68

3.3

Stimulation of HT-29 and THP-1 monocultures by LPS and live bacteria ..........69

3.4

Barrier function of PSIM layer to molecular diffusion ..........................................70

3.5

Barrier function and immune modulation by a PSIM gel layer in
response to VSL#3 ................................................................................................71

3.6

Mucus gel layer is not protective against motile Salmonella ................................72

3.7

The mucus layer regulates the extent of host-bacterial interactions and
the resultant immune responses ............................................................................73

4.1

S. typhimurium growth in co-culture with VSL#3 .................................................84

4.2

Mucus gel layer formation matching the thickness of colonic mucus ..................85

4.3

Chemokine (IL-8) and cytokine (TNF-α) levels in the mucosal barrier model .....86

xiii

4.4

Quantification of S. typhimurium crossing the epithelial barrier ...........................87

4.5

Chemokine (IL-8) and cytokine (TNF-α) levels from stimulated
epithelial (HT-29) and immune (THP-1) cells.......................................................87

4.6

S. typhimurium utilize the mucus barrier to escape competitive growth
inhibition from commensal bacteria and cause intestinal infection .......................90

5.1

PSIM ring formation in low pH ............................................................................90

5.2

Conceptual design of core-shell particles of PSIM for probiotic encapsulation ...91

5.3

Two-layer mucus barrier formation using PSIM ..................................................95

5.4

Luminal environment of the intestines is highly complex and
dynamically evolving ...........................................................................................100

5.5

Dynamically responsive mucus barrier in a microfluidic platform ....................101

5.6

Regulation of molecular diffusion via PSIM gel formation at the
lumen-mucus interface .........................................................................................102

5.7

Microfluidic platform to reconstitute the mucosal and immunological
function of the intestines .....................................................................................109

5.8

Fabrication of the microfluidic platform containing the collagen gel for
supporting epithelial cell layer and embedded immune cells .............................110

5.9

Testing the stability of the collagen gel and quantifying diffusion across the
gel layer ................................................................................................................111

5.10

Testing viability of embedded immune cells and coculture with live bacteria....112

5.11

Demonstrating epithelial and mucus layer formation and coculture with
live bacteria .........................................................................................................113

5.12

Demonstrating epithelial and endothelial layer formation in a single

xiv

microfluidic device .............................................................................................114
5.13

Intestinal stem cell isolation and growth into 3D organoids................................117

ADDITIONAL FIGURES
Figure

Page

2.S1

Quantification and removal of total DNA post PSIM extraction ........................136

2.S2

Theoretical quantification of total mucus on the luminal surface of
the pig intestines ..................................................................................................137

2.S3

Absorbance spectra of 2 % (w/v) PSIM in the pH range 2-7 ..............................138

2.S4

Rheological data showing the change in dynamic moduli (G՛ and G՛՛) of
PSIM (2% w/v) . ..................................................................................................139

2.S5

Gross image of PSIM compared to Porcine gastric mucin
(Type II, Sigma Aldrich)......................................................................................140

3.S1

Mucus layer thickness is concentration dependent . ............................................141

xv

CHAPTER 1
INTRODUCTION
The gastro-intestinal tract (GIT) performs essential functions in the human body. GIT is
responsible for the processing and digestion of food and absorption of essential nutrients
for survival. Apart from nutrient absorption, GIT maintains physiological homeostasis by
protecting the internal tissue from persistent chemical, physical, and microbial insults while
facilitating passage of desired molecules 1-3. GIT is the largest reservoir of bacteria in the
body with bacterial density as high as 1012 cfu/g 4 and houses almost 70% of the immune
system in the form of gut-associated lymphoid tissue (GALT) 5. The mucosal barrier along
the luminal side of GIT is essential for protection against the harsh luminal environment
along with development of the host immunity 6. This bio-barrier is composed of a cellular
epithelial barrier and an acellular mucus barrier. Acellular mucus barrier is the first line of
defense and physically separates the acid and digestive enzymes in the stomach and small
intestines, and dense bacterial population in the large intestines from underlying tissue.

The GIT mucosal barrier is unique due to its strategically modified anatomical structure,
cellular composition, mucus layer thickness and complex biochemical milieu. These
features are key to maintain the balance between absorption and protection from the
luminal compartment 7-9. The structural and environmental complexity, difficulty to access
the GIT, and dissimilar microbiota population have limited the use of live animal models
for studying dynamic interaction of mucosal barrier with luminal components that affect
the barrier function

10

. As a consequence, great progress has been made to recreate

intestinal cellular physiology

11

, three-dimensional (3D) morphology

1

12-13

, mechanically

active environment 14, and microenvironment compatible for host-microbe interactions 12,
15-17

in vitro. The in vitro systems allow the study of fundamental interactions between

different cell types of the intestine by eliminating biological complexity inherently present
in the tissue in vivo. In vitro functional human mucosal barrier models serve as an enabling
tool for understanding basic biology and disease progression in the gastrointestinal tract.
Recently, these models are becoming invaluable pre-clinical testing platforms for orally
administrated drug compounds and probiotics since they provide an effective, low cost and
high throughput way to gain useful information before performing cost-intensive animal
and human trials.

Intestinal epithelium is a monolayer of cells that are highly polarized and consist of the
absorptive enterocytes and the secretory goblet cells as major cell populations. In vitro,
Caco-2 cells are the most commonly used model system for mimicking the epithelium as
they spontaneously differentiate into mature enterocytes in culture that express
morphological features such as the brush border expression, tight junctions and surface
microvilli 18 that are similar to small intestine in vivo 19. HT-29 colon adenocarcinoma cells
cultured in medium without glucose also undergo enterocytic differentiation

20

. Further

advancement in this field was achieved by treating HT29 cell line with chemotherapeutic
drugs methotrexate and 5-fluorouracil. Treatment with these drugs caused differentiation
of HT29 cells into a goblet cell phenotype and with further selection stable mucus
producing cell lines HT29-MTX and HT29-FU were established 21-22. Co-culture of Caco2 and HT29-MTX cells at different cell ratios was shown to represent the in vivo like cell
population of the intestines. For example, a ratio of (9:1) Caco-2:HT-29 MTX closely

2

matched the Caco-2 monocultures that best represent the small intestinal cell population 23.
Extracellular matrix proteins like collagen, gelatin and Matrigel are used to recreate the
basement membrane that provides attachment sites and support for the epithelial cell
growth. Furthermore, these provide stimulation for epithelial cell expansion, spreading,
and differentiation 24.

For drug/nutrient absorption and transport studies, epithelial cells are seeded onto
permeable membrane supports made of polycarbonate and allowed to cover the entire
membrane as a monolayer

25

. These membrane supports known as transwell inserts fit

inside commonly used multi-well plates and create the apical and basolateral compartments
mimicking the luminal as well as the basal sections of the intestinal tissues. Caco-2 cell
monolayers in transwell inserts are the most commonly used model for drug transport
across intestinal epithelium 26. These monolayers have been heavily used by researchers to
mechanistically study transport of drugs, nutrients, etc. Caco-2 and Raji B cell co-culture
was used for M-cell like differentiation in transwells by normal

27

and inverted

28

configurations. M-cell like differentiation was used to study the process of transcytosis
across the monolayer which is commonly observed in the small intestine and important for
development of immunity. Finally, to incorporate a mucus layer in this model a triple coculture of Caco-2, HT29-MTX and Raji B was used 29

Mucosal interfaces are a major target for drug delivery and mucus layer is the first barrier
that a free drug or a drug delivery vehicle must overcome before reaching the cell surface
30-31

. Although there have been successful efforts in stimulating the cultured epithelial cell

3

lines to secrete mucus, the amount of mucus secreted is very small compared to in vivo. In
most cases mucus is observed in patches and does not fully cover the surface of epithelial
cell layer. Also, due to high variability in the culture conditions and the amount of mucus
produced under different culture conditions, researchers have applied mucus extracted
from excised tissues to cultured cell layers on transwell membranes

32

. This approach

provides multiple benefits over mucus secreting cell lines. A uniform layer of mucus can
be applied while most mucus secreting cell layers form non-uniform or patchy mucus layer.
The thickness of the mucus layer can be controlled precisely, whereas thickness control is
not feasible with the mucus secreting cell layers. The composition and the concentration of
mucus can be defined according to the organ system being mimicked. Experimental
variations can be reduced by pooling large quantities of extracted mucus or using
commercially available mucins. However, a few drawbacks of this approach are limited
availability of human derived tissues and therefore use of animal derived mucus and
potential cytotoxic effects of animal derived mucus on human cells.

Mucins are available commercially from different organs of animals but have been shown
to have significantly degraded properties compared to native mucus that may cause the
results of the studies to deviate from in vivo 33. Obtaining highly purified mucins require
very sophisticated and expensive instrumentation and expertise, therefore, due to easy
accessibility commercial mucins are used frequently in research studies. For example, an
artificial intestinal mucus was developed using commercially available porcine gastric
mucin and the rheological properties were matched with native pig intestinal mucus.
Further optimization was carried out to reduce cell death and have no effect on the barrier

4

integrity of the Caco-2 cell monolayer 34. The artificial mucus was applied to Caco-2 cell
monolayer in a transwell platform and permeability of hydrophilic (mannitol, FD4, FD10
and fluorescein isothiocyanate-bovine serum albumin) and hydrophobic (testosterone)
compounds was tested. Biosimilar mucus present on the epithelial cell layers acted as a
barrier to hydrophobic compounds and introduced a lag time for the diffusion of
hydrophilic compounds. Biosimilar mucus also showed more consistent results for creating
a steric barrier in comparison to native porcine intestinal mucus validating this approach to
model mucus barrier in vitro 35.

Three-dimensional cell cultures have been demonstrated to mimic organ physiology better
than traditional two-dimensional culture 36. Three-dimensional models of the intestine are
enabled recently by the development of microfabrication techniques like photolithography,
microcontact printing, and replica molding. These techniques have been coupled with
biomaterials that mimic the basement membrane of the intestinal tissue. 3D villous like
geometries have been created using collagen 31, 37, silicon 38, and poly lactic-glycolic acid
(PLGA)

39

. These studies demonstrated that Caco-2 epithelial cell differentiation and

polarization is dependent on the location along the villous like structures which mimic the
in vivo conditions. The researchers further tested the application of these models for
evaluation of probiotics Lactobacillus gasseri and E. coli Nissle 1917 in preventing
adhesion of pathogenic bacteria Salmonella typhimurium and Pseudomonas aeruginosa 40.
The model enabled the dissection of mechanisms by which different probiotic bacteria
exert their probiotic effect in a physiologically relevant environment.

5

Tubular constructs have been created using silk biomaterial that closely mimic the tubular
structure of intestines by including three-dimensional folds on the luminal side of the
constructs 12. The silk scaffolds were seeded with human myofibroblasts within the bulk
of the scaffold to add the mesenchymal cell component to support the epithelial cell growth
in the lumen of the model. Caco-2 and HT29-MTX were co-cultured in the lumen of the
scaffold. The tubular design and the three-dimensional luminal structure of the scaffold
enabled the luminal oxygen tensions to stay in the anaerobic zone for long term. Long term
(approx. 8 weeks) survival, mucus production and functional maintenance of cells in the
silk scaffolds provided great advantages for chronic studies alongside co-culture of live
anaerobic bacteria with epithelial cells. The system was utilized to study parasite-epithelial
cell interactions using Cryptosporidium parvum as a model organism

41

. The diarrhea

causing C. parvum successfully infected the model for 17 days and was serially transferred
to three new scaffolds to re-establish infection. 3D silk scaffolds were also used to study
toxic effects of Clostridioides difficile post germination and colonization 42. Toxigenic C.
difficile was significantly more toxic and caused higher epithelial cell death in the 3D
model compared to 2D transwells.

A major advance was achieved in the field of in vitro intestine modeling with the
development of ‘gut-on-a-chip’ platform. The microfluidic platform is made of
polydimethylsiloxane (PDMS) with two microfluidic channels separated by a thin porous
PDMS membrane. The porous PDMS membrane coated with Matrigel supported epithelial
cell growth on the apical side and endothelial cells on the basolateral side. The apical and
basolateral channels incorporated flows to mimic the luminal and vascular flow conditions.

6

Alongside flow, the system induced cyclic stretching of the PDMS membrane using a
pneumatic system and the epithelial cells were subjected to in vivo like peristalsis.
Epithelial (Caco-2) cells differentiated and polarized into villous like structures within 3
days compared to 3 weeks in transwell culture 11, 14. The system enabled co-culture of live
bacteria in the apical channel for more than 1 week without compromising epithelial cell
viability and was further used as a model for inflammatory conditions in the intestines 15.
This was achieved by culturing vascular endothelial cells on the basolateral side of the
PDMS membrane and flowing immune cells in the basolateral channel. By stopping the
membrane stretching, the system successfully captured bacterial overgrowth on the
epithelial cell layer leading to higher pro-inflammatory cytokine secretion and immune cell
infiltration. This system has been recently adapted to incorporate biopsy derived stem cell
organoids and induced pluripotent stem cell derived organoids that form the epithelial
layer, therefore, demonstrating the ability to create personalized intestinal model 43-44.

Current in vitro models of intestines can be broadly classified as static and dynamic models.
Static models such as transwell platforms and biomaterial scaffolds are commonly used for
molecular and drug diffusion or absorption studies. These models do not provide the
mechanically active environment that the cells experience in vivo. Also, static models are
not suitable for performing host-microbial co-cultures due to lack of mucus, flow, and
bacterial overgrowth. On the other hand, dynamic models can simulate in vivo like
mechanical forces by incorporating fluid flow and stretching. Under these conditions longterm co-culture of bacteria with human epithelial and immune cells has been demonstrated
either in the absence of mucus or using commercial porcine gastric mucin (PGM).

7

Despite significant progress in creating in vitro models of intestinal tissue with higher
complexity there are few challenges that remain unmet.
•

In vivo, a mucus layer tightly bound to epithelial cells physically separate bacteria
from coming in contact with the epithelial cells and communication occurs via
bacterial metabolites or host derived factors that diffuse across the mucus layer.
Such selective barrier function has been challenging to demonstrate in vitro.

•

Mucus secreting cell layers secrete very small amount of mucus compared to in
vivo tissues. Mucus layer thickness is an important mechanism for separating
bacteria and other luminal components that cause inflammation. The ability to
recapitulate this phenomenon in vitro will significantly improve physiological
significance of the in vitro mucosal barrier models.

•

Commercially available mucus fails to recapitulate the properties of mucus due to
enzymatic degradation and current mucus purification methods require extensive
instrumentation producing low quantities of mucus. Therefore, development of
methods for extraction of mucus that have intact functional properties will advance
the engineering of intestinal mucosa models.

Taking into consideration the recent progress in the development of engineered intestinal
models, current work aims to develop the basic technical strategies and platforms to
address the above stated challenges.
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CHAPTER 2
DEVELOPMENT OF A SCALABLE METHOD FOR MUCUS EXTRACTION
AND IN VITRO RECONSTITUTION OF AN INTESTINAL MUCUS LAYER

2.1 Introduction
The role of mucus in the intestines is incompletely understood. The mucus layer functions
as a selective biological barrier that permits transport of digested molecules while
protecting the underlying epithelial tissue1-3. The content in the lumen is continually
changing and the mucus layer must respond to its environment by being a barrier to some
components while being permeable to others2. The rheology and microscopic structure of
mucus affects its ability to prevent bacterial infiltration45-46. Many diseases involve
dysfunction of the mucus barrier, such as inflammatory bowel diseases47-49, cystic
fibrosis50, and colorectal cancer51-52. In diseased states, breakdown of the mucus
microstructure increases bacterial infection53-54. Two factors that have been shown to affect
these structural properties are the local pH and cation content55. An experimental model
that can expand the understanding of these mechanisms would be an essential tool to
address diseases of the intestines.

The mesh-like structure of the mucus barrier enables it to promote nutrient absorption while
acting as a barrier to infection. Mucus is primarily made up of mucin proteins. In both the
large and small intestine, mucus is composed predominantly of MUC2, one of the 21
known proteins in the MUC family56-57. In the small intestine, where most nutrient
absorption occurs, the mucus barrier is thin (20-100 µm thick), which facilitates molecular
transport while maintaining tissue sterility against luminal microbes58-59. In the large
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intestine, the mucus barrier is thicker (700-1,000 µm), which physically shields the
epithelial lining from the high density of the microbiota60-62. In the large intestine, the
mucus layer is composed of a tightly bound inner layer and a loosely bound outer layer63.
Secreted mucus traps invading bacteria which are eliminated with the luminal content64-65.

The local environment around the mucus layer greatly affects its structural properties. The
most well studied environmental factor is pH, which has a strong effect on the rheology of
mucus66-67. In acidic environments, mucus is elastic and gel-like, but in neutral and basic
environments, it behaves more like a liquid solution66. Mucin proteins have a bottlebrushlike structure with a protein backbone and glycan side chains68 (Figure 2.1A). At acidic pH
values, mucins change conformation and expose cysteine-rich hydrophobic regions on the
protein backbone, which leads to hydrophobic interactions and gelation69-70. In addition to
pH, other factors may affect the structure of mucus71. Calcium ions (Ca2+) plays an
important role in regulating intracellular mucin storage and secretion from goblet cells 55,
72

. The binding of Ca2+ with the glycan side chains causes dense packing of the mucin

polymeric chains55, 73-74. In the intestines, where the luminal pH is neutral75, dietary calcium
may have a greater effect on mucus structure and its barrier function. After ingesting food,
the availability of calcium and other ionic molecules in the gastro-intestinal tract is
increased76-77. Depending on the fed state, the luminal Ca2+ concentration varies between
5-20 mM76, 78.

Much of current in vitro research has used mucus extracted from the stomach79-80. It is
plentiful, less contaminated with bacterial components, and its extraction is
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straightforward. This material has been instrumental in demonstrating its pH dependent
behavior and barrier function67, 70, 81-83. Commercially available gastro-intestinal mucus is
derived from porcine stomachs. A limitation of this material is that gastric mucins have a
different biochemical structure from intestinal mucins. Gastric mucus is mostly MUC5AC
and MUC684, whereas the intestines is primarily MUC256. In addition, commercial mucin
has poor gel-forming capability85. This transition is an essential aspect of the primary
barrier function of mucus.

In the absence of a commercial source, there are two predominant methods used to study
intestinal mucus derived from rodent, large animal, or human tissues. The most common
is direct scraping of mucus from the wall of intestines. Scraped mucus has been used to
demonstrate that large nanoparticles, if properly coated, can rapidly penetrate mucus
compared to smaller nanoparticles86. It has also been shown that the interaction of mucus
with food associated stimuli such as lipids, calcium and pH significantly reduce the
transport of microspheres76. An important limitation of this scraping technique is that
contamination of unprocessed mucus with cellular debris can cause unwanted
immunological responses or cytotoxicity in vitro34. Alternatively, several studies have
purified the mucin proteins from intestinal mucus87-88. Purified mucins retain the
rheological properties of mucus89-90 and have been used to show that mucin chain
entanglement is dominant at neutral pH and high concentration91. At low pH the gel
formation is accompanied by formation of large‐scale heterogeneities within the mucin
solutions92. This purification method has limited yield, is time intensive and requires costly
specialized equipment, which limits its widespread use for effective recapitulation of
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mucus barriers with physiological thickness and concentration in vitro. In recent years,
little progress has been made in advancing mucus extraction protocols at large scale90, 9394

.

The goal of our study was to develop a method for extracting intestinal mucus and to
quantify the effect of environmental factors on its barrier properties. We hypothesized that
the permeability and barrier function of intestinal mucus is reversible and changes in
response to calcium ions in the local environment. To quantify these properties, the
extraction method needed to produce sufficient quantities of mucus that retained its pHresponsive rheology and contained minimal cellular contaminants. A systematic process
was used to determine the extraction conditions that would result in a high yield, cause
minimal cellular damage, and isolate mucus that would form a gel. Spectrometric and
rheometric measurements were used to quantify the absorbance and physical properties in
response to acidic and high calcium environments. The physical structure of mucus
proteins in these environments was determined by microscopy. The ability of mucus to
limit molecular diffusion and bacterial penetration was determined in an in vitro mucus
barrier model. This development of a high throughput extraction method will enhance
mucus research. Understanding the mechanisms that control the barrier function of mucus
will ultimately lead to better treatments of mucus-related diseases of the intestines.
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2.2 Results
2.2.1. Extraction of Natural Mucus
We have developed a new method to extract mucus from the porcine small intestines
(Figure 2.1B). The goal of the design process was to develop a method that isolates mucus
while retaining its pH-responsive rheology and minimizing the inclusion of cellular
contaminants. This method was based on the observation that after mucus is scraped from
the intestine, it dissolves in an alkaline solution. To determine the optimal solution to
dissolve mucus from the intestine in situ, washed intestinal tubules were filled with 1M
HCl, PBS or 1 M NaOH for 24 hours (Figure 2.1C). Before treatment, the intestinal lining
was undamaged, and mucus was tightly bound to the lining (Figure 2.1C, left). The pH of
the solvating solution affected the appearance of the intestine and the mucus layer (Figure
2.1C&D) and extent of solvation (Figure 2.1E). Filling the intestinal tubules with an acidic
solution (1 M HCl) for 24 hours turned the mucus layer into a whitish gel and the tissue
became rigid (Figure 2.1D, middle left). A neutral solution (saline) only partially
solubilized the mucus layer (Figure 2.1D, middle right). An alkaline solution (1 M NaOH)
dissolved most of the mucus layer and turned the viscera semi-solid (Figure 2.1D, right).
The total amount of protein in the alkaline solution was significantly higher (P<0.05) than
in the HCl and PBS solutions (Figure 2.1E).

The concentration of the alkaline solution affected the amount of protein recovery and the
extent of tissue damage (Figure 2.1F-H). Treatment with HCl (Figure 2.1F, middle left)
caused some tissue damage compared to untreated controls (Figure 2.1F, left). Treatment
with PBS did not significantly affect the epithelial tissue, which retained much of the
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villous architecture of untreated tissue (Figure 2.1F, middle right and inset). At a strength
of 1 M NaOH, the underlying epithelial tissue showed some damage and individual villi
were difficult to identify (Figure 2.1F, right). Treatment with a lower concentration of
NaOH (0.01 M), compared to 1M NaOH, reduced epithelial damage and retained villous
architecture (Figure 2.1G). Treatment with 0.1 M NaOH, produced comparable amounts
of recovered protein to treatment with 1 M NaOH (Figure 2.1H). The amount of recovered
protein significantly decreased after treatment with NaOH solutions of lower concentration
(0.01 M and below; P < 0.05; Figure 2.1H).

The amount of cellular contaminant proteins in the extracted mucus was reduced by
exploiting the reversible, pH-dependent sol-gel transition of mucin (Figure 2.1I). After
intestinal mucus was solubilized in 0.01 M NaOH, it was purified by a pH adjustment step.
The acidity of the solution was reduced to a pH of 4.0 and then increased to a value of 8.0.
When the pH was reduced, a gel formed (Figure 2.1B) enabling the supernatant to be
removed. One cycle of this pH-adjustment process reduced the total protein in the extract
by 40% (P < 0.05), but repeated sol-gel cycles did not significantly change the protein
content (Figure 2.1I). It took 4 sol-gel cycles to reduce the DNA content by 30% (P < 0.05;
Figure 2.1J). DNA contamination was reduced significantly by DNase treatment (P < 0.05;
Figure 2.S1). The removed supernatant did not gel at pH 4.0. After dialysis and
lyophilization, the entire process generated 1,274 ± 49 mg of dry protein per meter of
intestine. The theoretical amount of mucus in the intestine was calculated to be 1,775
mg/m, accounting for the increase in cross-sectional surface area due to plicae circularis
and villi structure (Figure 2.S2) (95-96). Compared to this theoretical value, PSIM extraction
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had a yield of 71.75 %. The final product reconstituted in a buffer medium was termed
porcine small intestinal mucus (PSIM).

2.2.2 Reconstituted PSIM Preserves Reversible pH Dependence.
The pH of PSIM affected its appearance, absorbance, rheological properties, and
aggregation. At pH 7, reconstituted PSIM (20 mg/ml) was optically clear and became
turbid at lower pH (Figure 2.2A, left and middle). High concentration PSIM (80 mg/ml)
was a viscous fluid that flowed in an inverted tube (Figure 2.2B left tube). At pH 4, high
concentration PSIM formed a gel that retains its shape in an inverted tube (Figure 2B right
tube). The turbidity of reconstituted PSIM increased with decreasing pH until a maximum
at pH 4 (Figure 2.2C top). This change in physical appearance matched the absorbance at
410 nm over this range (Figure 2.2C bottom). Reconstituted PSIM exhibited an absorbance
peak at 410 nm in the range from 290 to 790 nm (Figure 2.S3). The absorbance at pH 4
was significantly greater than at pH 7 (P < 0.05) and pH 2 (P < 0.05; Figure 2.2D) and the
greatest difference in absorbance was between pH 7 and pH 6 (P < 0.05).

The rheological properties of reconstituted PSIM matched the physical appearance and
absorbance. The viscous (G՛՛) and elastic (G՛) moduli were greater at pH 4 than at pH 7 (P
< 0.05; Figure 2.2D), matching the gel-like behavior at low pH (Figure 2.2B). Further
acidification to pH 2, reduced both moduli from that of pH 4 (P < 0.05; Figure 2.2D) similar
to the reduction in absorbance (Figure 2.2C). For all pH levels (2, 4, and 7), G՛ was greater
than G՛՛ (P < 0.05), and the greatest difference (more than 4 times) was at pH 4 (Figure
2D). The elastic modulus was greater than the viscous modulus over the entire frequency
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range from 1 to 68.3 rad/s (Figure 2.S4). At a microscopic level, pH affected the
aggregation of PSIM (Figure 2.2E). At pH 7 no aggregation was observed. At pH 6 and
below, microscopic aggregates were present (Figure 2.2E). The overall size and branching
of PSIM aggregates gradually increased with decreasing pH until a pH value of 4. At pH
values of 3 and lower, the size of the aggregates decreased. Area coverage increased with
decreasing pH until a value of 4 and then decreased as pH was reduced to a value of 2
(Figure 2.2F). The pH affected the physical properties of PSIM similarly. Each had its
highest value at pH 4. Absorbance correlated positively with the viscous modulus (R2 =
0.95), the elastic modulus (R2 = 0.90) and the area coverage (R2 = 0.9998).

The pH-dependent change in absorbance was reversible. As the pH of a PSIM solution was
rapidly changed from 8 to 4 and back to 8 (Figure 2.2G) the solution went from clear to
turbid and back to clear (Figure 2.2A). When this reversibility was quantified using
absorbance measurements and smaller pH intervals, the results matched the observed
changes in turbidity. Decreasing the pH of the PSIM solution from 8 to 4 increased
absorbance and it returned to a similar value as the pH was increased back to 8 (Figure
2.2G).

2.2.3 Barrier Function of PSIM is pH Dependent
The mucus barrier function changed with the pH and aggregation of PSIM. When a
bacterial solution was applied to a transwell membrane covered in PSIM, transmigration
of the bacteria resulted in an increase in bacterial density in the bottom well as a function
of time (Figure 2.3A-B). Two species of bacteria, Escherichia coli (Figure 2.3A) and
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Salmonella enterica serovar Typhimurium (Figure 2.3B), both transmigrated through
mucus. PSIM at pH 7, which had not formed a gel, significantly slowed E. coli
transmigration compared to a PSIM-free control (P < 0.05; Figure 2.3C). Salmonella
transmigration was not affected by the presence of PSIM at pH 7 (Figure 2.3B). At pH 4,
the aggregated PSIM significantly decreased transmigration of both bacteria (P < 0.05). At
pH 2, bacterial transmigration was significantly reduced compared to pH 7, while more
bacteria migrated across the mucus barrier compared to pH 4 (P < 0.05). These effects on
bacterial transmigration were significant at all time points (Figure 3A-B) and were
inversely correlated with PSIM aggregation (R2 = -0.97 for E. coli and R2 = -0.99 for
Salmonella; compare Figure 2.3C-D to 2F).

PSIM affected the motility of both Salmonella and E. coli at low pH (Figure 2.3E-H). In
PSIM at pH 7, the average speeds of E. coli and Salmonella were not different from PSIMfree controls (Figure 2.3F). At pH 4, aggregated PSIM significantly decreased the motility
of both species; the speeds of E. coli and Salmonella were slowed by 370% and 40%
compared to controls (P < 0.05, Figure 2.3F). In PSIM at pH 7, both bacterial species were
in a free-swimming state. In both aqueous controls and neutral pH PSIM, more than 80%
of the bacteria were motile with speeds of at least 2 µm/s (Figure 2.3G-H). In aggregated
PSIM at pH 4, the bacteria were immobilized. At pH 4, the presence of PSIM increased
the percentage of non-motile Salmonella and E. coli with speeds less than 2 µm/s from
35% to 54% and 12% to 87%, respectively (P < 0.05). Salmonella were more motile than
E. coli in PSIM at pH 4; there were fewer immobilized bacteria (speed < 2 µm/s; P < 0.05)
and more moderately motile bacteria (speed = 2 to 4 µm/s; P<0.05). The effect of pH on
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motility indicates how pH affected bacterial migration through layers of PSIM (Figure
2.3A-D).

2.2.4 Calcium Regulates PSIM at Neutral pH.
Calcium affected the microscopic and macroscopic properties of PSIM. The addition of
calcium at neutral pH increased the visible turbidity and absorbance of PSIM in a similar
manner to reducing pH (Figure 2.4). At pH 7, PSIM was optically clear. Increasing the
Ca2+ concentration proportionally increased the turbidity (Figure 2.4A). At pH 4,
increasing the Ca2+ concentration had no effect on the turbidity of PSIM. Similar to pH,
absorbance at 410 nm matched turbidity. At pH 7, increasing the Ca2+ concentration
significantly increased PSIM absorbance (P < 0.05), whereas, at pH 4, increasing the Ca2+
concentration did not affect the absorbance (Figure 2.4B). The effect of calcium on
absorbance was reversible. Addition of calcium chelating EDTA reduced the absorbance
that increased in response to the addition of calcium (P < 0.05; Figure 2.4C).

Calcium caused similar microscopic changes to PSIM as acidic pH. Small aggregates
formed at pH 7 with 1 mM Ca2+ (Figure 2.4D), whereas no aggregates formed without Ca2+
(Figure 2.2E). With 1 mM Ca2+, area coverage increased with pH until a value of 4 and
then decreased (Figure 2.4E) with a similar pattern to PSIM without calcium (Figure 2.2F).
The effect of calcium was greatest at neutral pH. The addition of 1 mM Ca2+ significantly
increased (P < 0.05) the area coverage (Figure 2.4E) compared to PSIM without calcium
(Figure 2.4E inset and 2F).

18

2.2.5. Calcium Controls the Thickness and Porosity of the Mucus Barrier.
At neutral pH, the Ca2+ concentration affected the thickness and permeability of PSIM.
When the Ca2+ concentration was 5 mM and above, PSIM formed visible layers after
overnight incubation as aggregated mucins precipitated (arrows in Figure 2.5A). No layers
formed when the Ca2+ concentration was 1 mM. The thicknesses of the mucus layers
increased linearly with Ca2+ concentration (P < 0.05; Figure 2.5B). The mucus layers
formed at different Ca2+ concentrations affected the transport of fluorescent FITC-dextran
in an unexpected manner (Figure 2.5C-D); the lowest transport was not observed in the
thickest layer. The FITC-dextran concentration, which resulted from diffusion through
PSIM layers, increased with time (Figure 2.5C). FITC-dextran transport was highest at 1
mM Ca2+, where there was no visible PSIM barrier (P < 0.05; Figure 2.5D). Transport was
lowest at 5 mM Ca2+ (P < 0.05). At Ca2+ concentrations of 10 and 20 mM, the transport of
FITC-dextran was greater than at 5 mM, even though the barriers were thicker (P < 0.05;
Figure 2.5D). This pattern was consistent for all time points (Figure 2.5C).

The differences in diffusion for the PSIM layers formed with different levels of Ca2+ was
caused by its microscopic structure. Calcium affected the size of PSIM aggregates, the
spacing between them and the total area of aggregated material. In the presence of 1 mM
Ca2+, PSIM formed microscopic, 2-5 µm diameter aggregates (Figure 2.6A). In 5 mM Ca2+
there were more aggregates of about the same size. At 10 and 20 mM Ca2+ PSIM formed
larger, branched aggregates (arrows in Figure 2.6A). At 5 mM Ca2+, the aggregates were
closest (Figure 2.6B). Most of spaces (> 95%) between the aggregates were less than 5 µm,
which was significantly greater than the aggregate spacing for 1 mM (P < 0.05). At 1 mM
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Ca2+, about half (49.8%) of the spaces were 5 - 10 μm, which was significantly greater than
the percentage of spaces at 5 mM (~ 5%; P < 0.05). At 10 and 20 mM Ca2+, there were
more large spaces (15 - 20 and 20 – 25 μm) between aggregates than at 1 and 5 mM (P <
0.05). At these higher Ca2+ concentrations, PSIM aggregates formed islands with low interparticle distances (< 5 µm) and higher distances (> 5 µm) between islands (Figure 2.6A).
These large spaces between islands created pores through the PSIM layers. At 1 mM Ca2+,
about 3% of the surface area was covered by PSIM aggregates (Figure 2.6C). Increasing
the Ca2+ concentration to 5 mM increased area covered 15-fold (P < 0.05). Further increase
in the Ca2+ concentration to 10 mM reduced the area coverage to 18%. Similar to the
aggregate distribution, no significant difference in the area coverage was observed if Ca2+
concentration was increased from 10 to 20 mM Ca2+.

Molecular retention within PSIM layers was dependent on Ca2+ concentration (Figure
2.6D-G). As with the transmitted light measurements (Figure 2.6A), the size of PSIM
aggregates increased with increasing Ca2+ concentration (Figure 2.6D). Green fluorescence
from FITC-dextran, which indicates the location of molecules retained in the PSIM layers,
became patchy with increasing Ca2+ concentration (Figure 2.6D). With an increase in
calcium concentration from 1 to 5 mM, the average GFP fluorescence decreased (P < 0.05;
Figure 2.6E), indicating a decrease in the number of molecules retained in the PSIM layer.
A further increase in calcium concentration to 10 mM, reversed this direction and increased
the average GFP fluorescence (P < 0.05; Figure 2.6E). The local structure of the PSIM
aggregates explains this behavior (Figure 2.6F). Regions of high PSIM aggregation (stars
in Figure 2.6F) had low GFP intensities. Pores in the PSIM layer, identified as regions with
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low red fluorescence (dashed circles in Figure 2.6F), had high GFP fluorescence. The GFP
intensity in the pores was greater than in the aggregated material (P < 0.05; Figure 2.6G),
indicating exclusion from PSIM aggregates.

2.3 Discussion
We have developed a new method for isolating mucus from the porcine intestine (Figure
2.1). This method dissolves the mucus layer from intact intestines using NaOH. A dilute
(0.01 M) solution was used because it dissolved most of the mucus layer (Figure 2.1E and
1G) and caused minimal damage to the epithelial cell layer (Figure 2.1F). Minimizing the
damage reduced the amount of contaminating proteins in the purified mucus (Figure 2.1G).
A sol-to-gel transition in the extraction method (Figure 2.1H) eliminated pH-unresponsive
macromolecules and cellular proteins without the use of high-cost instrumentation.
Solubilized mucus proteins were recovered with a yield of 1274 mg per meter length of
small intestine. The biophysical and biochemical properties of the produced mucus are in
line with those reported previously58, 66, 70, 81. At acidic pH values, PSIM becomes more
gel-like, with increasing viscous and elastic moduli (Figure 2.2D). With increasing
concentrations of calcium, the extent of PSIM aggregation at neutral pH increases (Figure
2.4B). The thickness of the PSIM layer formed in the in vitro mucus model has a thickness
comparable to the mucus layer in the small intestine58 (Figure 2.5B).

This new process has several advantages over other methods. Compared to direct scraping
of mucus from the epithelial lining, solubilization of mucus greatly simplifies the extraction
process. Dissolving mucus in dilute NaOH and purifying with a sol-gel transition
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significantly decreases contamination with cellular debris (Figure 2.1G). In immunogenic
experiments, contamination with cellular or bacterial component could cause unwanted
responses. In addition, the process is scalable and can be applied to entire lengths of PSI
tubes simultaneously. Compared to commercial mucin, PSIM retains the rheological
properties of natural mucus. Commercial mucins do not form a gel (Figure 2.S5), which
limits their use as a barrier in experiments in vitro33. Compared to mucin extraction
protocols, this process does not require extensive downstream equipment87-88. Most of
these methods are limited by the quantity and yield of mucus that can be produced, which
prevents the widespread use of mucus in research.

The extraction of large volumes of mucus enabled many of its properties to be quantified.
An important property that was observed was the reversibility of pH and calcium-induced
aggregation and gelation (Figure 2.2G and 2.4C). Reversibility suggests that the properties
of mucus respond to conditions in the local environment. This dynamic change was easily
monitored because the absorbance at 410 nm was directly correlated to the degree of
aggregation (Figure 2.2C and 2.2F) and the viscous and elastic moduli (Figure 2.2D).
Reconstituted PSIM retained the ability to be a barrier to bacterial penetration (Figure 2.3)
and this property was dependent on pH. At neutral pH, mucus only minimally prevented
penetration, but when the mucus aggregated at lower pH, penetration was considerably
reduced (Figure 2.3A-D). The aggregation of the mucus at pH 4 appeared to slow
penetration because the bacteria became immobilized in aggregated mucus. A gel layer of
PSIM can act like a natural barrier by controlling molecular diffusion and bacterial
transmigration.
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Another observation was that calcium plays a critical role in the intestinal milieu. Similar
to pH, the availability of calcium ions affected the thickness of the mucus layer (Figure
2.5B). Increasing the calcium concentration increased PSIM aggregation, suggesting that
calcium affected PSIM by similar mechanisms as changes in pH. In addition, there was an
interplay between the responses of mucus to pH and calcium. Overall, acidic pH had a
greater effect on mucus aggregation than calcium concentration within the physiological
range (Figure 2.4B). At neutral pH and in the absence of calcium, mucus was not
aggregated. Increasing the calcium concentration increased mucus aggregation but did not
reach the same extent as that observed at pH 4 (Figure 2.4B). Calcium-driven aggregation
also affected the barrier function. From low (5 mM) to high (20 mM) physiological levels
of calcium 76, 78, the molecular permeability of mucus increased (Fig 2.5C).

The microscopic structure of mucus explains how calcium controls the barrier function of
mucus. The primary microscopic features that affects the physical properties of mucus are
the arrangement and density of aggregates. At very low calcium levels (1 mM), mucus
aggregation is minimal (Figure 2.6A). At low physiological calcium concentrations (5
mM), small and uniform aggregates begin to appear. At higher calcium concentrations (10
- 20 mM), larger, more branched aggregates form. The branching of mucin aggregates did
not increase once Ca2+ concentration was higher than 10 mM. Although the density of
aggregates increases, this condensation decreases the surface area coverage (Figure 2.6C).
The branched nature of the aggregates formed void spaces in the mucus layer (Figure 2.6D)
that increase molecular diffusion while also increasing the thickness of the layer (Figure
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2.5A). The structure and extent of these aggregates explains how calcium increased both
mucus layer thickness and molecular transport.

These effects suggest how the local calcium concentration controls the properties of the
mucus barrier (Figure 2.7). The increased concentration of ionic molecules after ingesting
food (predominantly calcium) induce mucin aggregation and increases the thickness of the
mucus barrier. The increased aggregation increases molecular permeability (Figure 2.6),
while simultaneously increasing resistance to microbial penetration from the lumen. If the
behavior of PSIM in high calcium is similar to pH 4, where both had considerable
aggregation (Figure 2.4B), then PSIM aggregation at high calcium would also have high
resistance to microbial penetration from the lumen (Figure 2.3 and Figure 2.5). Therefore,
dense branched aggregates increase the open channels for molecular diffusion while also
creating a network to ensnare invasive microbes. As the mucus flows along the epithelium
its viscoelastic and barrier properties change in response to the lumen content. Because the
properties of the mucus are reversible, it is instantaneously responsive and serves different
functions in different intestinal environments, e.g. an empty lumen and one directly after
eating.
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Figure 2.1 Extraction of porcine small intestine mucus (PSIM). (A) Schematic of mucin
microstructure, stable polymeric chains at neutral pH, hydrophobic interactions of cysteine
rich regions at acidic pH (dashed circles), and ionic interactions between calcium ions
(Ca2+) and negatively charged glycans at neutral pH. (B) Mucus extraction procedure
starting with direct solubilization of the mucus layer with NaOH, and separation of pH
responsive mucus via reversible sol-gel transition. (C) PSI tubules after 24 hours exposure
to 1 M HCl, PBS, and 1 M NaOH. (D) The luminal surface of PSI tissue sections after 24
hours exposure to HCl, PBS, and NaOH. (E) Recovered protein with solutions of different
pH, relative to PBS. (*, P < 0.05; n = 3). (F) Hematoxylin and Eosin (H&E) stained
histological sections of PSI tissues treated with different pH solutions. Inner panels show
individual villi. (G) H&E stained PSI section after 0.01 M NaOH treatment. (H) Total
protein extracted when PSI tubules were filled with NaOH solutions ranging from 0.001
M to 1 M (n = 3). (I) Total protein content with repeated sol-gel cycles relative to initial
total protein extracted. (J) Total DNA content with repeated sol-gel cycles relative to the
total DNA initially present in the PSIM extract. (*, P < 0.05)
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Figure 2.2 Response of PSIM to pH. (A) PSIM (20 mg/ml) in 20 mM HEPES at pH 7.3
was clear. At a pH of 5.3 the PSIM solution was turbid. Returning the pH to 7.2, after
decreasing it to 5.3, restored optical clarity. All solutions were at 20 mg/ml concentration
unless otherwise noted. (B) PSIM (80 mg/ml) in 20 mM HEPES at pH 7 was a viscous
solution (left tube, left image) that flowed after inversion (left tube, right image). At pH 4,
PSIM was a gel (right tube, left image) that did not flow after inversion (right tube, right
image). (C, top) Droplets of PSIM (20 mg/ml) on a glass slide imaged using a stereoscope.
Darkness was due to the turbidity of the droplets. (C, bottom) Absorbance of PSIM
solutions (20 mg/ml) at different pH values at a wavelength of 410 nm. (D) Dynamic
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rheological moduli (G՛ and G՛՛) of PSIM at pH 2, 4, and 7 and at 1 Hz and 37oC (n = 3,
mucus from individual pigs). (E) Microscopic images of PSIM between two glass
coverslips in the pH range 2-7. Insets show close-up images of aggregates. (F) Surface area
covered by PSIM aggregates per image (as in panel E) in the pH range 2-7 (n = 10). (G)
Real-time sampling and characterization of the reversible aggregation of PSIM in the pH
range 4-8. The solid line represents an increase in the absorbance as the pH was reduced
from 8 to 4 (red arrows). The dotted line represents the decrease in absorbance (blue
arrows) as the pH was increased from 4 to 8 (n = 3; *, P < 0.05).
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Figure 2.3. Barrier function of PSIM. (A) Time-resolved transmigration of E. coli
through 3 µm pore transwell membranes layered with PSIM at pH 7, 4, and 2. Controls
were HEPES buffer at pH 7 without PSIM (n = 3). (B) Transmigration of Salmonella. (C)
Number of E. coli that migrated across the PSIM layers at 6 h time point. (D) Number of
Salmonella that migrated across the PSIM layers at 6 h. (E) The speeds of individual
bacteria were measured in hanging drops of PSIM mixed with bacteria and suspended
above the objective of an inverted microscope. At pH 7 (top), velocities (indicated by line
lengths) were greater than at pH 4 (bottom), where all bacteria were visibly non-motile. (F)
The average speeds of E. coli and Salmonella in PSIM at pH 4 were significantly lower
than PSIM-free controls at pH 4 (*, P < 0.05; n = 3). At pH 7, PSIM had no effect on
bacterial motility compared to control. (G) Distribution of speeds of E. coli in PSIM at pH
4 and 7 compared to controls (HEPES buffer without PSIM; n = 3). The percentage of
bacteria with speeds less than 2 µm/s was greater in PSIM at pH 4 compared to pH 7 and
controls (*, P < 0.05). The percentage of bacteria swimming at 5 µm/s was lower in PSIM
at pH 4 compared to pH 7 and controls (*, P < 0.05). (H) The distribution of speeds of
Salmonella in PSIM at pH 4 and 7 compared to controls was functionally similar to E. coli.
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Figure 2.4. Calcium regulates the physical properties of PSIM. (A) Stereoscope images
of PSIM at pH 4 and 7 with Ca2+ ranges from 0 to 10 mM. Scale bar is 1 mm. (B) The
absorbance of PSIM at 410 nm and pH 7 increased with increasing Ca2+ concentrations of
0, 1, 5 and 10 mM (*, P<0.05; n = 3). Absorbance did not change at pH 4. (C) The
absorbance of PSIM at 410 nm and pH 7 with 100 μl Ca2+ (+Ca2+) was greater than control
PSIM without Ca2+ (*, P < 0.05; n = 3). A second addition of 100 μl Ca2+ (++Ca2+) further
increased absorbance. The absorbance was reduced by adding 100 μl EDTA (+EDTA), a
Ca2+ chelator, compared to +Ca2+ and ++Ca2+ (*, P < 0.05). Inset images are snapshots of
PSIM solutions at the different Ca2+ conditions. Scale bar is 10 mm. (D) Microscopic
images of reconstituted PSIM (2% w/v) between two glass coverslips in pH range 2-7 with
1 mM Ca2+. Insets show close-up images of the aggregates. (E) The surface area covered
by PSIM aggregates with 1 mM Ca2+ was greatest at pH 4 compared to pH 2- 3 and pH 56 (*, P < 0.05; n = 10). At pH 7 (inset), The surface area covered by PSIM aggregates with
1 mM Ca2+ was greater than the area covered by PSIM aggregates without Ca2+ (*, P <
0.05).
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Figure 2.5. Calcium controls the thickness of the mucus barrier. (A) Cross-section
images of PSIM gel layers formed on transwell membranes at 1, 5, 10, and 20 mM Ca2+
and pH 7. (B) PSIM layer thickness increased linearly with Ca2+ concentration. The
thicknesses at 10 and 20 mM were greater than at 5 and 10 mM, respectively (*, P < 0.05;
n = 3). (C) Concentration of FITC-dextran after transport through a PSIM layer formed on
a transwell membrane in the presence of 1, 5, 10, and 20 mM Ca2+ at pH 7. (D)
Concentration of FITC-dextran at 6 hrs after transport through the PSIM layers in (C). The
concentration was greatest with 1 mM Ca2+ compared to all other concentrations (*, P <
0.05; n = 5). The concentration of FITC-dextran was less at 5 mM compared to 10 and 20
mM Ca2+ (*, P < 0.05).
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Figure 2.6. Calcium controls the porosity of the mucus barrier. (A) Microscopic images
of PSIM aggregates at 1, 5, 10, and 20 mM Ca2+ and pH 7. Higher resolution images show
homogeneous, dense, and small PSIM aggregates at 5 mM Ca2+. (B) Distribution of
distances between PSIM aggregates as a function of Ca2+ concentration. The percentage of
distances less than 5 µm was greater at 5 mM compared to 1, 10 and 20 mM (*, P < 0.05;
n = 5). The percentage of distances between 5 and 10 μm was greater at 1 mM compared
to 5 mM (*, P < 0.05). The percentage of distances between 15 and 25 μm was greater at
10 and 20 mM compared to 1 and 5 mM (*, P < 0.05). (C) The surface area covered by the
PSIM-aggregates at 5 mM was greater than at both 1 and 10 mM Ca2+ (*, P < 0.05; n =
10). (D) Fluorescent microscopic images of Cy5-lectin-tagged PSIM layers (red, left) and
overlaid with FITC-dextran (green, right) at 1, 5, 10, and 20 mM Ca2+. (E) The average
GFP fluorescence (in relative fluorescence units, RFU) was less at 5 mM compared to 1,
10 and 20 mM (*, P < 0.05; n = 5). (F) Expanded images of pores (dashed lines) and
aggregates (stars) formed in PSIM layers at 10 and 20 mM Ca2+. (G) The fluorescence
intensity of FITC-dextran in pores was greater than in aggregates at both 10 and 20 mM
Ca2+ (*, P < 0.05; n = 5).
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Figure 2.7. Role of calcium as a regulator of molecular transport. Proposed dynamic
regulation of the thickness and permeability of the small intestine mucus barrier in response
to available luminal calcium ions that fluctuate between meals.
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2.4 Materials and Methods
All chemicals and supplies were purchased from Fisher Scientific and Sigma Aldrich
unless otherwise specified.

2.4.1 Natural mucin extraction from a porcine small intestine
Small intestines from freshly slaughtered pigs were obtained from a local slaughterhouse
and transported to the laboratory on ice within 2 hours. Porcine small intestines (PSIs) were
cut into 6-inch long segments and washed with running DI water. The tissues were filled
with 50 ml of 1M HCl, 1x PBS, and 1M NaOH. After both ends are tied, PSI tubules were
incubated at 4 ºC for 24 hours. The solutions were collected and aliquoted into 1 ml
Eppendorf tubes and centrifuged in a microcentrifuge at 10,000 x g for 30 minutes. The
supernatant was collected, and total protein was quantified using a Bradford assay. Bovine
serum albumin was used as a standard for known protein concentration. For optimization
of NaOH concentration, cleaned PSIs (6-inch, n=3) were filled with 10 ml of serially
diluted NaOH solutions (1, 0.1, 0.01, and 0.001 M) and incubated at 4 ºC for 24 hours. The
solutions were collected and stored at -80 ºC. To quantify total soluble protein, the frozen
solutions from all four conditions were thawed at 4 ºC, vortexed thoroughly, and divided
into 1 ml aliquots. The aliquots were centrifuged in a microcentrifuge at 10,000 x g for 30
min. Supernatant from 3 aliquots were dialyzed against DI water in a cellulose membrane
(molecular size cut-off = 14 kDa) for 72 hours at 4 ºC with a water change every 12 hours.
The dialyzed solution was lyophilized to quantify the dry mucus weight and reconstituted
at an equal concentration in DI water to quantify total protein content using a Bradford
assay.
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For the scale-up, PSIs (2 meter) were flushed with running tap water to remove the luminal
content and the loosely bound mucus layer. The luminal space was then filled with 350 ml
0.01 M NaOH with both ends tied and incubated at 4 °C for 24 hours. The solubilized
mucus extract was collected and centrifuged at 20,000 x g for 2 hours at 4 ºC to precipitate
debris in 50 ml tubes. After collecting the clear supernatant, the pH was adjusted to 4 to
induce PSIM aggregation. Aggregated PSIM was separated by centrifugation at 200 x g
for 15 minutes and resuspended to get a clear solution in sterile DI water by adjusting pH
to 8.0-8.5. The solubilized PSI was filtered through a 40 μm strainer and dialyzed
(molecular size cut-off = 14 kDa). The dialyzed mucus extract was sterilized by adding 1%
(v/v) chloroform under constant stirring at 4 ºC for 72 hours. The sterile solution at a pH
of approximately 7, was frozen at -80 ºC, lyophilized, and stored as a powder at -20 ºC
until used. All the experiments were conducted using the lyophilized powder reconstituted
in an appropriate buffer or cell culture medium and the term PSIM is used to denote the
reconstituted form at a known concentration. The theoretical density of mucin protein in
the intestine was calculated by considering the surface area increased due to the intestinal
folds and the villous architecture.

2.4.2 Histological sectioning of the intestinal tissues
Tissues were cut into 2 cm sections and excess water was removed. Tissues were embedded
in optimum cutting temperature (OCT) cryomatrix and snap frozen in liquid nitrogen.
Using a cryostat (Thermo Scientific, CRYOSTAR NX70), frozen tissues were sectioned
at a 20 µm thickness. Sections were fixed with 10 % formalin and stained with hematoxylin
and eosin (H&E).
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2.4.3 Biophysical characterizations of the reconstituted mucus
1. Rheological characterization. Bulk rheology on reconstituted PSIM samples from 3
different pig intestines was conducted. Small amplitude oscillatory shear measurements
were performed in a Kinexus Pro rheometer (Malvern Instruments, U.K.) using a cuvette
cell geometry. PSIM samples were loaded into the cup at pH values of 2, 4, and 7 and held
at a constant temperature of 37 °C. Oscillatory frequency sweeps were conducted between
1 and 100 Hz at a constant 0.25 % strain.

2. Absorbance characterization. PSIM aggregation was quantified using UV-vis
spectroscopy. The absorbance value at 410 nm was used as a measure of PSIM aggregation.
Lyophilized PSIM powder was reconstituted in 20 mM HEPES at pH 7. The pH value of
the reconstituted PSIM was adjusted using 2 M HCl and 2 M NaOH. 100 μl of PSIM
samples were added to a 96-well plate and the absorbance was measured using a microplate
reader (Synergy H1, BioTek).

3. Microscopic characterization of PSIM aggregates. Twenty microliter droplets of
PSIM solution were placed between glass coverslips and clear glass slides and were imaged
using a brightfield microscope (EVOS). The images were binarized using a built-in scheme
in the image analysis software ImageJ. The area covered by aggregates per image was
quantified and plotted as percentage area covered normalized by the total area of the image.

4. Dynamic viscoelastic characterization. PSIM 2 % (w/v) at pH 7.3 was added to a glass
vial and subjected to constant stirring. The pH was monitored in real time using a needle-
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type pH probe (PreSens) and was adjusted using 2N HCl and 2N NaOH solutions. Samples
were collected at specific pH values for UV absorbance measurements.

2.4.4 Bacterial cell culture
Two bacterial strains S. typhimurium (SL1344) and E. coli (MG1655) were used for live
bacterial experiments. Frozen stocks of the bacterial strains were inoculated in Luria Broth
(LB) and grown overnight. Optical density at 600 nm (OD600) of the overnight cultures
was measured and the bacteria were seeded at a density of 1x107 in fresh LB medium and
allowed to grow to an OD600 of 0.6-0.8 and used for further experiments.

2.4.5 Two-dimensional bacterial motility assay in PSIM on a glass slide
Live bacterial imaging was performed in a hanging drop assembly for bacterial motility
quantification. Bacteria cultured in LB were diluted 1:10 in PSIM (2 % w/v) or control (20
mM HEPES solution), and a 2 μl droplet was added on top of a circular cover glass. The
cover glass with the droplet was inverted and rested on top of a 1mm thick PDMS ring
bound to a glass slide. The glass slide with the hanging drop was imaged using an inverted
fluorescent microscope (Zeiss). Bacterial movement was tracked in a single 2D plane and
the average speed was quantified using the in-built particle tracker plug-in ‘Trackmate’ in
ImageJ software.

2.4.6 Three-dimensional bacterial diffusion assay through PSIM in transwell inserts
HEPES solution (20 mM) was added to transwell inserts (50 μl/transwell) and used as the
no barrier condition and compared to 50 μl of PSIM 2 % (w/v) at pH values of 2, 4, and 7.
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Transwell inserts were placed into the wells of a 24-well plate containing 600 μl of LB. A
100 μl of live bacterial culture (1011 cells/ml) was gently added to the inserts and the plates
were incubated at 37 ºC and 5 % CO2. Fluorescence intensity was measured at 1-hour
intervals for 6 hours in the bottom well and converted to colony forming units (CFUs)
using a previously established standard curve.

2.4.7 Fixation and cryo-sectioning of PSIM layers on transwell membranes
Transwell inserts with different PSIM gel layers formed in response to added Ca2+ were
held vertical. A small cut was created on the edge of the membrane from the bottom side.
The inserts were kept on tissue paper to absorb all liquid from the membrane and mucin
gel. Transwell inserts were transferred into wells of 24 well plate containing 600 μl of 10%
formalin solution in PBS. Formalin (10% in phosphate buffered saline) solution was gently
added on the apical side of the transwell and kept at room temperature for 10 minutes.
Inserts were moved to a different well and the formalin solution was carefully replaced by
PBS 3 times on apical and basal sides. The membranes were dehydrated again using tissue
paper and carefully cut out from the inserts using a scalpel. The membranes were embedded
in OCT and snap frozen in liquid nitrogen. Frozen membranes were cross sectioned at a 10
µm thickness using a cryostat and collected on glass slides. The sections were imaged using
a bright field microscope (EVOS) and the thickness of the gel layers was calculated using
ImageJ.
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2.4.8 Lectin staining for visualization of PSIM aggregates
Far-red-fluorescence (Cy5)-conjugated Sambucus Nigra (SNA) lectins (Vector Labs) were
added to PSIM 2 % (w/v) at a final concentration of 10 µg/ml and incubated at room
temperature for 30 minutes. The solution was dialyzed against DI water for 24 hours
constant stirring in a dark room at 4 ºC. The fluorescent lectin tagged PSIM was used to
visualize PSIM aggregates using fluorescence microscopy.

2.4.9 Pore size distribution
Aggregates were imaged microscopically in PSIM (2 % w/v) containing 1, 5, 10, and 20
mM Ca2+. Inter-aggregate distance was measured at 100 random locations per image using
ImageJ. An average number distribution (%) of at least 5 independent images from each
condition was plotted in a range of 0 - 30 μm. FITC-dextran diffusion was measured at
different calcium concentrations. HEPES solution (20 mM) was added to the wells of a 24
well plate (600 μl/well). PSIM solution 2 % (w/v) in 20 mM HEPES at a pH of 7 and
containing 1, 5, 10, and 20 mM Ca2+ was added to transwell inserts (100 μl/transwell).
Transwell inserts were placed into the wells of 24 well plates containing 600 μl of HEPES
solution and the well plate was incubated for 12 hours at 37 ºC and 5 % CO2 to allow for
mucus layer formation. A 10 μl droplet of 10 mg/ml solution of FITC dextran (MW= 20
kDa) in DI water was gently added to the inserts and the plate was incubated at 37 ºC and
5 % CO2. Fluorescence intensity was measured at 1-hour intervals for 6 hours in the bottom
well and converted to concentration of FITC dextran.
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2.4.10 Fluorescent imaging and area overlap analysis
PSIM 2% (w/v) at pH 7 and containing 1, 5, 10, and 20 mM Ca2+ was added to a 96-well
plate (100 μl/well). The well plate was incubated overnight at 37 ºC and 5 % CO2 to allow
for mucus layer formation. FITC-dextran (MW = 20 kDa) at a concentration of 10 mg/ml
in 20 mM HEPES was gently added to the transwells (10 μl/transwell) and the plate was
incubated at 37 ºC and 5% CO2. Fluorescent images using were captured using a Zeiss
Axiovert 4-laser spinning disc confocal microscope (20x magnification) after 1 hour.
Image analysis for GFP intensity (FITC-dextran) and RFP intensity (Cy5 lectin tagged
PSIM) was performed using ImageJ and normalized for the total area of the images. Areas
with bright RFP intensity were considered as ‘aggregate’ and low RFP intensity areas as
‘pore’. The average intensity of FITC was determined in the entire image and in the pore
and aggregate regions.

2.4.11 Statistical analysis
A two-tailed Student’s t-test assuming unequal variances was used for statistical analysis
of different conditions. One-way ANOVA with Bonferroni post-hoc test was used for
multiple comparisons. Differences were considered significant at p < 0.05. All data are
presented as a mean ± standard deviation.
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CHAPTER 3
MODEL OF INTESTINAL MUCOSA TO QUANTIFY THE ROLE OF MUCUS
AND EPITHELIAL BARRIER IN REGULATING THE HOST INNATE
IMMUNE RESPONSES TO PROBIOTIC AND PATHOGENIC BACTERIA

3.1 Introduction
In the intestines, three major components mediate the host-response to pathogens and the
gut microbiota: the mucosal barrier, the epithelial layer and tissue-resident immune cells
97

. The interactions of these components in pathophysiological conditions are poorly

understood. Two major disease states result from disruption of these protective
mechanisms, acute enteropathogenic infections, and chronic inflammatory bowel diseases
(IBD) 98-99. The mucus layer is the first line of defense, which plays a critical role in the
prevention of enteropathogenic infections. In the healthy colon, the secreted mucus layer
that covers the entire epithelium minimizes interactions of commensal bacteria with host
cells

63, 100

. Dysfunction of the mucus layer and bacterial infiltration are linked to tissue

inflammation and disease

47, 49, 101-102

. During enteropathogenic infections, bacteria can

penetrate intestinal regions of disrupted mucus

103-105

bacteria can also penetrate regions with intact mucus

, but there is recent evidence that
106

. A better understanding of the

interaction between microbes and the protective host mechanisms could lead to improved
treatment for intestinal diseases.

The responses of epithelial and immune cells to bacterial infiltration are difficult to
decouple from in vivo measurements and are poorly understood. The epithelial barrier and
cells of the innate immune system collectively function as the subsequent layers of
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protection after the mucus layer

107

. In the colon, tight junctions between epithelial cells

prevents transmigration of pathogens into underlying tissue

108

. Colonic epithelial cells

produce chemokines, such as interleukin-8 (IL-8), that attract neutrophils and other effector
cells of the innate and adaptive immune system 109. Monocytes, which are innate immune
cells, detect pathogens directly as well as respond to epithelial derived signals. One
response to these stimulants is differentiation into macrophages and dendritic cells

110-111

.

LPS and flagellin are common pathogen associated molecular patterns (PAMPs) that bind
to toll-like receptors (TLR4 and TLR5) and activate the downstream pathways that cause
pro-inflammatory cytokine secretion

112-114

. Immune-cell-derived tumor necrosis factor

(TNF-α) is a cause of systemic inflammation. Both TNF-α and IL-8 levels are significantly
upregulated in the intestines of patients with IBD 115-116.

A common enteropathogenic infection is Salmonellosis 117-118. Salmonella enterica subsp.
enterica serovar Typhimurium is a foodborne pathogen that causes diarrhea and can often
be fatal

118

. In humans, infection with Salmonella or other enteropathogenic bacteria is

linked to higher incidence of IBD 119-121. Studies have shown that attachment of Salmonella
to mucus is a critical step for infection

122-125

. In mouse models, Furter et al. showed that

Salmonella infects the colonic epithelium even when covered with a thick layer of mucus
106

. This recent observation contradicts the common notion that the mucus barrier serves as

a sticky net to trap the invading luminal microbes 126. How Salmonella penetrate the mucus
barrier and the effects of this penetration on epithelial and immune cells is not fully
understood.
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Murine models are the most common method to study the gastrointestinal biology.
However, studying the complex interactions between luminal microbes, tissue immune
cells and the mucosal barrier in living animals is challenging. Alternately, in vitro platforms
are well suited to studying these complex interactions. For example, three-dimensional
biomaterial platforms have been developed to mimic the morphology of the epithelial layer
12, 127

. Epithelial and immune cell interactions are commonly measured in transwell-based

platforms 128-129. Flow based microfluidic platforms have enabled long-term co-culture of
gut-representative microbial communities

16-17, 130

. Incorporation of mechanical forces

within microfluidic platforms induced three-dimensional villus differentiation and allowed
quantification of communication between bacteria-epithelial-immune cell compartments
11, 15, 130

.

The inclusion of a mucus layer is critical because of its role in mediating bacteria-epithelial
cell interactions. Some cultured epithelial cells secrete mucus and form mucus layers that
enable the quantification of drug and molecular interactions with mucus 131-132. Two recent
studies demonstrated thick mucus layer secretion from primary human colonic epithelial
cells using air-liquid interface in transwell culture or colon-on-a-chip microfluidic culture
133-134

. Most cultured cell lines, however, do not generate a layer matching physiological

thickness of colonic mucus. Due to insufficient mucus secretion from cultured human
epithelial cells, porcine gastric mucin (PGM) has been used as human mucin substitute 3435

. PGM has been used to recreate the intestinal mucus layer by mixing with agar and

forming a solid interface with luminal solution that supported bacterial attachment and
growth

16-17

. However, stomach mucus has different physicochemical properties than
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intestinal mucus and commercially available PGM does not undergo sol-gel transitions 135.
An alternative to PGM is purified intestinal mucus. It has been shown that MUC2, which
is purified from intestinal mucus, has antiviral activity and attenuates the virulence of
pathogenic bacteria 136-137. We have developed a method to extract porcine small intestinal
mucus (PSIM). Reconstituted PSIM undergoes sol-gel transitions with changes in pH and
ion concentrations, similar to native intestinal mucus

138

. Low pH caused mucus

aggregation and reduced bacterial transport, and moderate calcium concentrations formed
microscopic aggregates that impeded molecular diffusion.

Here, we demonstrate a model of intestinal mucosa to quantify the role of mucus and
epithelial barrier in regulating the host innate immune responses to probiotic and
pathogenic bacteria. We hypothesize that mucus prevents the penetration of bacteria
through the intestinal lining and that the motility of pathogenic bacteria affects their
penetration and immune response. To decouple the host-microbe interactions, mucus and
epithelial layers were developed in a physiological form on transwell membranes. The
porous transwell membrane enabled molecular communication between human epithelial
(HT-29) cells and human monocytic (THP-1) cells. The hypotheses were tested with
commensal VSL#3 bacteria, wild-type SL1344 Salmonella, and a non-motile flhDC
knockout strain of Salmonella. Bacterial penetration, immune cell differentiation, and
cytokine release were quantified using fluorescent immunostaining, microscopic imaging,
and ELISA. The effects of a mucus layer on bacterial transmigration and molecular
diffusion were quantified using fluorescent spectroscopy. This intestinal mucosa model
enabled the quantification of the differences in the integrity of mucosal barrier compared
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to epithelial barrier alone when challenged with live bacteria. This mucosal barrier model
enabled the measurement of bacterial penetration, immune cell differentiation and cytokine
release. Understanding the mechanisms of action of probiotics or pathogens when in
contact with the mucosal barrier will lead to development of therapies for bacterial
infections and immunological diseases of the intestine.

3.2 Results
3.2.1 PSIM formed a gel layer on top of epithelial cells without affecting cell
viability.
We have developed a method to mechanistically study the host-microbe interactions at the
mucosal interface of the intestines. A mucus gel layer was reconstituted on top of epithelial
cells growing on transwell membranes (Figure 3.1). Human colonic epithelial cells (HT29) genetically labeled to express red fluorescent protein (RFP) covered the entire surface
of the transwell membrane and coverage was not affected by the presence of PSIM (Figure
3.1A). PSIM (20 mg/ml) was added to the epithelial cells and after 12 hours it formed an
opaque gel layer in situ that was structurally porous (Figure 3.1B). This 12-hour incubation
at 37 °C reduced the thickness of the PSIM layer (Figure 3.1C). Initially, the total height
of solubilized PSIM (100 µl/well) layered on top of epithelial cells was approximately 2.7
mm. Final thickness of the gel layer formed was 880 ± 230 µm (Figure 3.1B). The PSIM
gel layer formation was robust and the structure was maintained after cryo-freezing and
histological sectioning. PSIM formed a tightly bound gel layer and did not affect the
viability of HT-29 cells (Figure 3.1D). No significant difference was observed in the live
(green) and dead (red) cell area coverage between the presence and absence of a PSIM
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layer (Figure 1E). DAPI (4′,6-diamidino-2-phenylindole) staining of PSIM (red) showed
that the PSIM gel layer has a fibrous structure (Figure 1F). When added, fluorescent wild
type Salmonella (green) were suspended in the three-dimensional mucus matrix (Figure
3.1F).

3.2.2 PSIM is not immunogenic to epithelial or immune cells.
To test its immunogenicity with human-derived cell lines, reconstituted PSIM was directly
added to the monocultured HT-29 and THP-1 cells. PSIM mostly did not induce a proinflammatory cytokine and chemokine response from HT-29 and THP-1 cells. HT-29 cells
were cultured on the apical side of 24-well transwell inserts (Figure 3.2A) and IL-8 and
TNF-α were quantified in the basolateral medium. HT-29 cells secreted a small but
significantly higher amount of IL-8 in response to PSIM when compared to HT-29 cells
alone (P < 0.05, Figure 3.2B). There was no difference in the amount of TNF-α secreted
from HT-29 with and without PSIM application (Figure 3.2C). THP-1 cells were cultured
in suspension in 24 well plates and IL-8 and TNF-α quantified in the culture medium
(Figure 3.2D). PSIM did not induce IL-8 or TNF-α secretion from THP-1 cells compared
to cells without PSIM (Figure 3.2E, F).

3.2.3 Immunological responses from epithelial and immune cells are stimulant
dependent.
When cultured independently, HT-29 and THP-1 cells respond differentially after direct
contact with bacterial antigen LPS, a set of 8 live probiotic bacteria (VSL#3), and
pathogenic bacteria Salmonella. Intestinal epithelial cells have regular incidence of
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bacterial contact, but immune cells only come in direct contact with live bacteria during
bacterial infection events. The amounts of pro-inflammatory chemokine (IL-8) and
cytokine (TNF-α) secreted from epithelial and immune cells were stimulant dependent.
Salmonella induced a robust chemokine response in HT-29 cells, causing approximately
24-fold higher IL-8 secretion compared to unstimulated cells (P < 0.01, Figure 3.3A).
Direct contact of HT-29 cells with LPS or VSL#3 did not increase IL-8 secretion (Figure
3.3A). LPS-stimulated THP-1 cells secreted 61-fold more IL-8 compared to unstimulated
cells (P < 0.01, Figure 3.3B). Direct contact with VSL#3 and Salmonella each caused an
approximately 30-fold increase in IL-8 secretion from THP-1 cells compared to bacteriafree controls (P < 0.01, Figure 3.3B).
There was no increase in the level of TNF-α secreted by HT-29 cells after direct contact
with LPS or live bacteria compared to unstimulated cells (Figure 3.3C). TNF-α secretion
from THP-1 cells was significantly increased when cultured with LPS or live bacteria
(Figure 3.3D). LPS induced the highest TNF-α secretion and the level of TNF-α was 342fold higher compared to unstimulated THP-1 cells (P < 0.01, Figure 3.3D). Direct contact
of THP-1 cells with VSL#3 (P < 0.01) and Salmonella (P < 0.05) caused 77 and 20-fold
increases in TNF-α, respectively (Figure 3.3D).
The morphology of THP-1 cells changed significantly when cultured in direct with VSL#3
(Figure 3.3E). Change in morphology indicates the differentiation into macrophage and
dendritic-like cells. THP-1 cells stimulated with VSL#3 induced approximately 6-fold
increase in the number of differentiated cells per millimeter squared area (P < 0.01, Figure
3.3F). Stimulation with LPS or Salmonella did not induce a change in morphology and
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cells were mostly round (Figure 3.3E). Collectively, the results show that epithelial and
immune cell activation and immunological responses are stimulant dependent.

3.2.4 A PSIM gel layer prevents LPS induced immunogenic responses.
In the co-culture platform, we hypothesized that the mucus layer would act as a physical
barrier for molecular diffusion. Mucus layers prevented pro-inflammatory chemokine and
cytokine secretion by human epithelial and immune cell co-culture in response to bacterial
products. To test this hypothesis, epithelial-immune cell co-culture was used with and
without mucus (Figure 3.4A). Co-culture of the HT-29 and THP-1 cells did not affect the
basolateral levels of IL-8 and TNF-α when compared to monocultures (compare without
mucus and without LPS in Figure 3.4B, C to Figure 3.2B, C, E, F). The addition of PSIM
on the apical side of the epithelial layer caused no change in the levels of IL-8 and TNF-α
(Figure 3.4B, C). LPS increased the concentrations of both IL-8 (P < 0.05, Figure 3.4B)
and TNF-α (P < 0.05, Figure 3.4C) 4-fold in the absence of a PSIM layer. The presence of
a mucus layer significantly reduced the levels of IL-8 (P < 0.05, Figure 3.4B) and TNF α
(P < 0.05, Figure 3.4C) after LPS stimulation. The total amounts of IL-8 and TNF-α from
the co-cultures were significantly lower compared to direct stimulation of THP-1 cells by
LPS (P < 0.05, compare Figure 3.4B, C to Figure 3.3B, D). Collectively, the results show
that the epithelial barrier attenuates immune cell stimulation by preventing direct contact
of immune cells with bacteria derived molecules, and the mucus layer further increases this
barrier function.
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3.2.5 A PSIM gel layer is a barrier to migration of live probiotic bacteria.
To investigate the barrier function of the mucus layer in presence of commensal bacteria,
we added a commercial probiotic mix VSL#3 to the HT-29 and THP-1 co-culture and
measured the bacterial transmigration across the epithelial layer and the corresponding
cytokine and chemokine responses. Without mucus, bacteria transmigrate across the
epithelial layer to the bottom well (Figure 3.5A). The mucus layer reduced bacterial
transmigration by 7-fold (P < 0.05, Figure 3.5B). Bacterial transmigration in the absence
of a mucus layer induced THP-1 cell differentiation characterized by changes in
morphology from round to elongated (Figure 3.5A). A 11-fold higher number of
differentiated cells per millimeter squared surface area were present without the mucus
layer when compared to the conditions containing a mucus layer (P < 0.01, Figure 3.5C).
Due to increased bacterial loads, significantly higher concentrations of both IL-8 and TNFα were measured in the bottom well (P < 0.01, Figure 3.5D and P < 0.05, Figure 3.5E). The
mucus layer reduced the IL-8 concentration by 16-fold (Figure 3.5D) and TNF-α
concentration by 7-fold (Figure 3.5E). Immunohistostaining showed the spatial
arrangement of the epithelial cell layer expressing epithelial cell adhesion molecule
(EpCAM) at the base and the mucus layered on top of the epithelial surface. VSL#3
bacteria that stained positive for nuclear stain DAPI were mostly seen on the outer surface
of the mucus layer and few or no bacteria were present deeper in the mucus layer (Figure
3.5F). Collectively, the results show that a reconstituted mucus layer reduced bacterial
transmigration, thereby preventing direct contact between commensal bacteria and
epithelial cells. The barrier effect leads to reduced epithelial damage by bacteria and
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reduced proinflammatory cytokine and chemokine responses from the underlying immune
cells.

3.2.6 A PSIM gel layer enhances the transmigration of Salmonella.
To test if active motility enables bacteria to transmigrate across the mucus layer, we used
motile Salmonella. Surprisingly, the presence of mucus significantly increased the
transmigration of wild type Salmonella and 3-fold more Salmonella transmigrated across
the epithelial cell layers in presence of mucus (P < 0.05, Figure 3.6A). In the HT-29 and
THP-1 co-culture, wild type Salmonella significantly increased the amounts of IL-8 and
TNF-α in the presence of mucus and an epithelial layer compared to an epithelial layer
alone (P < 0.05, Figure 3.6B, C). To test if these effects are controlled by flagella, a flagellar
knockout (ΔflhDC) strain of Salmonella was created. The knockout caused a loss in
Salmonella motility and the mean velocity was similar to VSL#3. Mean velocity of wild
type Salmonella was significantly higher compared to the knockout strain and VSL#3 (P <
0.05, Figure 3.6D). The presence of a mucus layer reduced the transmigration of knockout
Salmonella across the epithelial cell layer (P < 0.05, Figure 3.6A). The amount of IL-8 was
significantly lower in presence of a mucus layer compared to epithelial cells alone for
knockout Salmonella (Figure 3.6B). The concentration of TNF-α in the medium with
knockout Salmonella with or without a mucus layer (Figure 3.6C) was equivalent to basal
levels from an unstimulated co-culture of cells (Figure 3.4C). Immunostaining showed the
flagella of wild type Salmonella and the lack of flagella of knockout Salmonella (Figure
3.6E). Histological sections of the mucosal layers on transwell membranes showed wild
type Salmonella embedded deeper into the mucus layer (Figure 3.6F) than VSL#3 (Figure
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3.5F). Within the gel layer, a significantly higher number of bacteria were found at the top
and center of the mucus layer compared to the area proximal to the epithelial surface
(Figure 3.6G). Collectively, these results show that motile Salmonella, in presence of
mucus, utilize flagellar motility for higher transmigration across the mucus and epithelial
layers. Higher transmigration caused significantly higher immune responses from the
epithelial-immune cell co-culture.

3.3 Discussion
To gain a deeper understanding of how commensal and pathogenic bacteria interact with
the mucosal lining of the intestine, we created an in vitro model of this barrier which
consisted of a mucus layer, an epithelial cell layer and cells of immune system. These
components represent essential complexities of the mucosal barrier. With this model we
showed that the mucosal layer decreased the penetration of LPS and non-motile bacteria
(Figure. 3.4&3.5). All bacteria tested in this study induced the production of cytokines and
chemokines by THP-1 monocytes (Figure 3.3B, D). Additionally, Salmonella induced the
production of IL-8 by HT-29 epithelial cells. In contrast, VSL#3 did not induce epithelial
IL-8 production (Figure 3.3A, C). These results indicate that epithelial cells tolerate contact
with commensal bacteria but respond to pathogens, whereas innate immune cells respond
to all bacterial contact.

This intestinal mucosa model was built upon the commonly used transwell platform, which
enabled creation of epithelial and mucus gel layers, and co-culture with bacteria and
immune cells (Figure 3.1). The mucus was not cytotoxic (Figure 3.1) and was
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biocompatible to human epithelial and immune cells (Figure 3.2). The thickness of the
mucus gel layer can be adjusted to match the thickness of mucus in different compartments
of the gastro-intestinal tract (Figure 3.S1). The mucus layer caused spatial segregation of
live commensal bacteria away from the epithelial layer and enabled co-culture studies up
to 24 hours. The mucosa model demonstrated key mucus-layer-associated processes that
have been reported in animal models but are difficult to reproduce in vitro.

In this model, both mucus and epithelial cells formed a physical barrier to molecular
diffusion and bacterial penetration. The amounts of IL-8 and TNF-α produced in the coculture system without mucus (Figure 3.4B, C) were lower than THP-1 cells directly
stimulated with same amount of LPS (Figure 3.3B, D). When mucus was present, these
amounts were further reduced (Figure 3.4). In the absence of the mucus layer, more bacteria
crossed the epithelial cell layer (Figure 3.5D) and more monocytes differentiated (Figure
3.5E). This dependence indicates that the mucus layer helps maintain the integrity of
epithelial barrier in presence of commensal bacteria. The lack of production of TNF-α by
epithelial cells indicates that inflammation is only induced after a breach in epithelial
barrier and direct contact of live bacteria with immune cells.

As a barrier, the mucus layer was more effective at preventing penetration of commensal
bacteria (Figure 3.5) than immunogenic molecules (Figure 3.4). The transmigration of nonmotile commensal bacteria (VSL#3) across the epithelial layer was significantly lower in
presence of mucus (Figure 3.5). With mucus, the amounts of IL-8 and TNF-α induced by
VSL#3 were very low (Figure 3.5), similar to the amounts produced by unstimulated
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epithelial and immune cells (-LPS in Figure 3.4). The difference in penetration between
bacteria and molecules was most likely because of the structure of intestinal mucus. The
mucus gel layer was porous as shown by histological sectioning and fluorescent confocal
microscopy (Figure 3.1B, F). After gelation, intestinal mucus forms islands of aggregated
protein that permit easier transmigration of small molecules than microbes and particulates
138

.

An unexpected result was that the presence of mucus increased the penetration of
Salmonella through the intestinal barrier (Figure 3.6). In comparison, mucus reduced the
penetration of LPS (Figure 3. 3), and non-motile commensal bacteria (Figure 3.5).
Salmonella transmigration followed complete penetration of the mucus layer and the
epithelial barrier (Figure 3.6A). This effect was surprising because the penetration of
Salmonella through mucus and an epithelial layer was greater than through an epithelial
layer alone (Figure 3.6A-E), which was considerably thinner (Figure 3.1B). Flagella were
required for this increase in transmigration through mucus (Figure 3.6A-E), showing that
this phenomenon is dependent on bacterial motility. Two explanations for this observation
are that mucus increases the motility of Salmonella by (a) attracting flagellated Salmonella
or (b) inducing the production of flagella.

The intestinal barrier responded in distinct ways to immunogenic molecules. The primary
immunogenic molecules in Salmonella are LPS and flagellin, which are detected by tolllike receptors (TLR) 4 and 5, respectively

113, 139

. When LPS was applied to THP-1

monocytes, they did not differentiate (Figure 3.3F). The LPS successfully crossed both the

52

mucus and epithelial barriers as indicated by the secretion of IL-8 and TNF-α (Figure 3.4).
This result show that monocyte differentiation after contact with bacteria (Figure 3.3E) is
controlled by a mechanism that is independent of LPS and TLR4. When knockout
(ΔflhDC) Salmonella were applied to the intestinal barrier model, the THP-1 monocytes
did not produce TNF-α (Figure 3.6C). This result suggests that the production of TNF-α is
mediated by TLR5, the primary toll-like receptor to detect the flagella of Salmonella.

Combined, these results paint a picture of how the intestinal barrier could react to contact
with bacteria (Figure 3.7). In the healthy condition of an intact mucus layer and a lumen
filled primarily with commensal bacteria (condition 1, Figure 3.7A), no bacteria penetrate
the barrier layer and no cytokines are produced. When there is physical damage to the
mucus layer (condition 2, Figure 3. 7B), commensal bacteria penetrate the epithelial layer
and trigger the production of cytokines and chemokines by monocytes (Figure 3.5F, G).
After this contact, the monocytes differentiate into macrophages and dendritic cells (Figure
3.5C, E). Chemokines, e.g. IL-8, recruit neutrophils to contain the infection. When motile
Salmonella are present in the lumen in significant amounts (condition 3), the mucus layer
does not prevent penetration (Figure 3.7C). In this condition, the epithelial layer produces
chemokines (Figure 3.3A) to recruit neutrophils before the pathogens cross the epithelial
barrier. Once this barrier is breached, monocytes are activated, producing a similar immune
response to an infection of commensal bacteria (Figure 3.3B, D and 6C, D).

The intestinal mucosa model presented here provided insights into the role of mucus and
epithelial barrier against bacteria and bacteria-derived molecular factors in presence of
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innate immune cells. We envision that this platform will be useful for screening host
response against pathogenic, opportunistic, and probiotic strains of bacteria. Many of the
obtained results could only have been obtained with an in vitro system that includes the
three essential components of the mucosal barrier: mucus, epithelial cells and immune
cells. For example, it was found that the epithelial barrier is a key component of the innate
immune response to bacterial infection, especially in the detection of pathogens. A better
understanding of the relation between microbial pathogens, the intestinal barrier and the
immune system has the potential to improve treatment of infections and immunological
diseases.

3.4 Materials and Methods
All chemicals and supplies were purchased from Fisher Scientific and Sigma Aldrich
unless otherwise specified.

3.4.1 Human cell culture
HT-29 (ATCC, HTB-38) adherent cells were cultured in McCoy’s 5A medium (Sigma
Aldrich) supplemented with 2.2 g/L sodium bicarbonate. THP-1 (ATCC, TIB-202)
suspension cells were cultured in RPMI-1640 medium (containing 0.05 mM βMercaptoethanol). HEK293T/17 (ATCC, CRL-11268) cells were cultured in Dulbecco’s
Modified Eagle Medium (DMEM). All media were supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin and referred to as complete medium in the
methods. Cells were maintained in a 37 oC humidified incubator with 5% CO2.
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RFP-expressing HT-29 cells were made by lentivirus transfection. For lentivirus
production, HEK293T/17 cells grown in a 10 cm dish were transfected with four plasmids
acquired from addgene: (4 μg pLV-mcherry (Cat #36084), 2 μg pMDLg/pRRE (Cat
#12251), 2 μg pRSV-Rev (Cat #12253) and 2 μg pMD2.G (Cat #12259), using the standard
calcium-phosphate co-precipitation method. Virus was harvested 24 h post transfection and
filtered through 0.45 μm filter. For transduction, HT-29 cells cultured in six well plates
were cultured in equal volumes of the virus containing medium and complete McCoy’s 5A
medium. Cells were monitored for RFP expression and sub-cultured after most cells
expressed RFP when checked for fluorescence qualitatively.

3.4.2 PSIM extraction and purification
PSIM was extracted as described before 138 with changes in sterilization procedure. Briefly,
intact small intestine tubules were cut into 2-meter lengths and rinsed with water to
eliminate food particles from the lumen. The tubules were drained gently, and the lumen
was filled with 350 ml of 0.01 M NaOH. The ends of the tubules were tied and incubated
for 24 hours at 4 oC. After incubation the solubilized material was drained by squeezing
and collected. The extract was subjected to centrifugation at 20,000 x g (Thermo Scientific)
at 4 oC for 2 hours to remove insoluble debris. The supernatant was collected without
disturbing the precipitate. The clear supernatant was subjected to sol-gel transition by
adjusting the pH to 4 using 2 M HCl. The aggregates formed at pH 4 were subjected to
centrifugation at 200 x g for 15 minutes and resolubilized in sterile DI water by adjusting
the pH value to 8. The solution was passed through a 40 μm strainer and subjected to
dialysis using a membrane with molecular size cut-off equal to 14 kDa. The dialyzed
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mucus extract was sterilized by adding 1% (v/v) chloroform under constant stirring at 4 ºC
for 72 hours. The solution (30 ml aliquots) was transferred to 50 ml conical polypropylene
tubes, frozen to -80 oC, and freeze dried (Labconco Freezone 2.5L freeze dry system). The
freeze-dried mucus was reconstituted aseptically in serum- and antibiotic-free McCoy’s
5A medium. The solutions were sterilized in 15 ml polypropylene tubes by adding 10%
chloroform and allowing to sit at 4 oC for 24 hours without shaking. The chloroform
solution formed a distinct layer at the bottom and mucus solutions were collected without
disturbing the interface under aseptic conditions. The solutions were aliquoted in 1.5 ml
polypropylene tubes and stored at -80 oC until use.

3.4.3 Bacteria culture
Probiotic VSL#3 bacteria were acquired from a commercial source (VSL Pharmaceuticals,
Inc.) and stored at 4 oC until use. For co-culture experiments, the freeze-dried bacteria were
aseptically reconstituted in serum- and antibiotic- free McCoy’s 5A medium at a cell
density of 1010 CFU/ml. Bacterial cells were incubated at 37 oC for 1 hour to recover. After
1 hour, the cell density was diluted to required cell density by serial dilution.

Wild type Salmonella strain SL1344 was used for live motile bacterial experiments. The
ΔflhDC SL1344 strain was created using a modified lambda red recombination procedure
140

. SL1344 was transformed with plasmid pkd46 by electroporation. Single colonies were

inoculated into 50 ml of LB supplemented with 100 μg/ml of carbenicillin and grown at 30
o

C. Once the absorbance at 600 nm (OD600) of the culture reached 0.1, arabinose was

added to the culture to a final concentration of 20 mM and grown until the OD600 was
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equal to 0.8. Bacteria were centrifuged at 3000xg for 10 minutes and washed twice with
nanopure water (Millipore). Bacterial pellet was resuspended in 400 µl of nanopure water.
In a polypropylene tube, 1 µg of DNA (PCR amplification of pkd4 using the primers, 5’FOFZCACGGGGTGCGGCTACGTCGCACAAAAATAAAGTTGGTTATTCTGGgtctt
and

gagcgattgtgtaggc-3’

5’-

ZZFFACAGCCTGTTCGATCTGTTCATCCAGCAGTTGTGGAATAATATCGGaattag
ccatggtccatatgaatatc-3’) was mixed with 50 μl of resuspended Salmonella. Bacteria were
electroporated in a 1 mm cuvette (Fisher Scientific catalog # FB101) with the following
settings on the electroporation system (BIORAD, GenePulser Xcell): Voltage = 1.8 kV,
Capacitance = 25 μF, Resistance = 200 Ω, and 5 ms time constant. Primers were purchased
from Invitrogen, where FOFZ are phosphorothioated nucleotides corresponding to ATAC
and ZZFF correspond to TTAA. After electroporation, bacteria were recovered in 1 ml of
LB for 2 hours at 37 oC. The recovery solution was plated on agar plates supplemented
with kanamycin (50 μg/ml) and incubated at 37 oC overnight. Positive colonies were
regrown on kanamycin plates overnight at 43 oC in order to eliminate pkd46 from the
bacteria. Salmonella were transformed with a plasmid encoding for GFP under the control
of constitutive Plac promoter using electroporation as discussed above. The cultures were
stored at -80 oC in 25% glycerol solution.

For experiments, frozen stocks of the Salmonella strains were inoculated in LB medium
and grown overnight at 37 oC. Small amount of overnight culture was inoculated in fresh
LB medium and allowed to grow to a density of 4 x 108 CFU/ml and used for further
experiments. To prepare bacteria for transwell co-culture experiments, bacteria culture was
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subjected to centrifugation at 2500 x g for 10 minutes. The bacterial cell pellet was washed
three times with PBS by gentle pipetting multiple times and repeating the centrifugation
step in between. Final pellet was reconstituted in serum- and antibiotic-free McCoy’s 5A
medium and the required cell density was adjusted by serial dilution.

3.4.4 Epithelial cell seeding in transwell inserts
For transwell assays, HT-29 cells were detached from culture flasks using trypsin and
seeded at a density of 105 cells per insert in 3 μm pore size polycarbonate membrane
transwell inserts (CLS3415, Corning). Inserts were cultured for 7 days in 24 well plates in
complete McCoy’s medium. The culture medium was changed 24 hours after cell seeding
and every 48 hours after that. After day 7, the culture medium was aspirated from the
transwell inserts. The inserts were washed three times with PBS on both the apical and
basolateral sides. To check for incomplete cell coverage, inserts were filled with 250 μl of
PBS and the change in liquid level was checked for 5 minutes. The inserts with no change
in liquid level were used for further experiments. To check for coverage microscopically,
inserts were seeded with RFP-expressing HT-29 cells. After 7 days of culture, the inserts
were imaged using EVOS FL Auto imaging system (Life technologies). Images captured
using a 10x objective were tiled using in-built EVOS software.

3.4.5 Mucus layer formation and cytotoxicity of PSIM on epithelial cells
To form mucus layers, HT-29 cells were cultured for 7 days in the transwell inserts and
layered with 100 μl of sterile PSIM (20 mg/ml). Inserts were incubated in a 37 oC
humidified incubator with 5% CO2 for 12 hours.
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For testing cytotoxicity of PSIM, HT-29 cells were cultured for 7 days in the transwell
inserts and washed three times with phosphate buffer saline (PBS). The inserts were
transferred to a new 24 well plate and 600 μl of serum- and antibiotic-free McCoy’s 5A
medium was added to the basolateral side. To form the mucus layers, 100 μl of thawed
PSIM was added to the apical side. For controls, 100 μl of serum- and antibiotic-free
McCoy’s 5A medium was added to the apical side. The plates were incubated for 24 hours
at 37 oC. The viability of HT-29 cells after application of the PSIM layer was performed
using a viability/cytotoxicity assay kit (Cat # L3224, Invitrogen). The transwell inserts
were transferred to a fresh 24-well plate containing 600 µl of phosphate buffer saline (PBS)
and rocked gently. The PBS was replaced three times to wash the bottom surface of the
transwell membrane. Finally, the wash solution was replaced with PBS containing 2 µm
Calcein AM and 4 µm Ethidium homodimer-1 and incubated for 30 minutes at room
temperature. Fluorescent images were acquired using Zeiss Spinning Disk Axio Observer
Z1 microscope (Carl Zeiss) with a C-Apochromat 63x oil immersion objective and Zen
software. To quantify area coverage, fluorescent images of the stained cells were
background subtracted and segmented to isolate green (Live) and red (Dead) signal. The
percent area covered by positive signal from green and red channels was quantified relative
to the total image area.

To visualize bacteria embedded in the mucus gel, 103 CFU/ml wild type GFP Salmonella
were mixed in the PSIM solution prior to adding it to transwell inserts covered with HT29 cells (as above). After incubation at 37oC for 12 h, the cells and mucus in the inserts
were fixed using 10% formalin solution in phosphate buffer saline for 20 minutes. The
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membranes were cut from the inserts and washed in PBS three times. The mucus gel layer
was separated from the membrane and the cells, transferred onto a coverslip and stained
with DAPI, which identified the mucus gel under UV light. GFP-expressing Salmonella
embedded in PSIM gel were imaged using Zeiss Spinning Disk Axio Observer Z1
microscope (Carl Zeiss). Z-stack images were captured with a 63x oil immersion objective
at 1 μm height intervals using Zen software. Three-dimensional rendering and image
processing were performed using Imaris (Bitplane, Belfast, UK).

3.4.6 Immunological response of epithelial and immune cells to PSIM
For testing immunogenicity of PSIM, HT-29 cells cultured for 7 days in the transwell
inserts were washed three times with phosphate buffer saline (PBS). The inserts were
transferred to a new 24 well plate and 600 μl of serum- and antibiotic-free McCoy’s 5A
medium was added to the basolateral side. Mucus layers were formed by adding 100 μl of
thawed PSIM (20 mg/ml) to the apical side. For controls, 100 μl of serum- and antibioticfree McCoy’s 5A medium was added to the apical side. The plates were incubated for 24
hours at 37 oC. The media from the basolateral side was collected. Manufacturers protocol
was followed to quantify human IL-8 (Cat # DY 208) and human TNF-α (Cat # DY 210)
concentrations using DuoSet ELISA assay kit (R&D Systems). Assays were calibrated to
the standard curve created for serially diluted IL-8 and TNF-α standard solutions on each
plate per assay.

Cultured THP-1 cells were washed three times with PBS. After centrifugation, 105 THP-1
cells were suspended in serum- and antibiotic-free medium (600 μl); seeded into 24 well
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plates; and 100 μl of thawed PSIM (20 mg/ml) was directly added to the medium. After 24
hours of incubation at 37 oC, the media were collected and the concentrations of human
IL-8 and TNF-α were quantified using ELISA assays.

3.4.7 Direct stimulation of HT-29 and THP-1 monocultures
Twenty-four well tissue culture treated plates were seeded with 105 HT-29 cells per well
and cultured for 4 days with a media change every day. After 4 days, the cells were washed
with PBS three times and replaced with 450 μl serum- and antibiotic-free McCoy’s
medium. To each well, 50 μl of medium was added that contained bacterial endotoxin
lipopolysaccharide (LPS, 10 μg/ml) from Escherichia coli O55:B5 (Cat # L6529), VSL#3
(2 x 109 CFU/ml), or Salmonella (2 x 105 CFU/ml). Media alone (50 μl) was added to
control wells. After 12 hours of incubation at 37 oC, the media were collected. Human IL8 and TNF-α concentrations were quantified using ELISA assays.

Using a similar procedure as above, 105 THP-1 cells were suspended in serum- and
antibiotic-free medium (600 μl); seeded into 24 well plates; and stimulated with 50 μl LPS
(10 μg/ml), VSL#3 (2 x 109 CFU/ml), and Salmonella (2 x 105 CFU/ml). After 12 hours of
incubation at 37 oC, the medium was collected and the concentrations of human IL-8 and
TNF-α were quantified using ELISA assays.

3.4.8 Construction of in vitro mucosal lining model
Epithelial cells were grown on transwell inserts and checked for coverage and leakage
using PBS as described above. Mucus layers was formed by adding 100 μl of sterile PSIM
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(20 mg/ml) and incubating at 37 oC for 12 hours. For controls without mucus, 100 μl serumand antibiotic-free McCoy’s 5A medium was added to the apical side of the inserts. In
cultures of THP-1 cells, the medium was removed by centrifugation and the cells were
washed with PBS three times. The cell pellet was suspended in serum- and antibiotic-free
McCoy’s 5A medium. The medium in the basolateral side of the transwell inserts was
replaced with 600 μl of THP-1 cell suspension at a density of 105 cells/well.

3.4.9 LPS interaction with in vitro mucosal lining model
The in vitro mucosal lining model was challenged by adding 50 μl per well LPS (10 μg/ml)
from Escherichia coli O55:B5 (Cat # L6529) to the apical side of the transwell inserts in
the presence and absence of a pre-formed PSIM layer. After 24 hours of incubation with
LPS, the medium from the bottom well was collected for quantification of human IL-8 and
TNF-α using ELISA.

3.4.10 VSL#3 interaction with in vitro mucosal lining model
The in vitro mucosal lining model was challenged by adding 50 μl per well of VSL#3
culture (2 x 109 CFU/ml) to the apical side of the transwell inserts. After 24 hours of
incubation at 37 oC, the transwell inserts were removed and brightfield images of the
bottom well containing THP-1 cells were captured using EVOS FL Auto imaging system
(Life technologies). The contrast of the images was uniformly enhanced. Post-imaging, the
medium was collected from the bottom well. Half of the medium was used for
quantification of human IL-8 and human TNF-α with ELISA. The other half was used for
bacterial quantification by serial dilution, plating on solid agar plates and incubated at 37
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C for 24 hours. The colonies were manually counted and converted to CFU based on the

dilution factor. The THP-1 cell morphology change was manually quantified using ImageJ
(NIH). Differentiated immune cell were identified as cells having stretched or dendrite-like
morphology. The number of cells was normalized by the total area of the images.

3.4.11 Salmonella interaction with in vitro mucosal lining model
The in vitro mucosal lining model was challenged by adding 50 μl per well of GFP-labeled
Salmonella (2 x 105 CFU/ml) to the apical side of the transwell inserts. After 12 hours of
incubation at 37 oC, the transwell inserts were removed. Using a plate reader (Synergy H1,
BioTek Instruments, Inc.), the GFP intensity was quantified in the bottom well plate to
measure of bacterial cell density. The medium was collected and used for quantification of
human IL-8 and human TNF-α with ELISA.

3.4.12 Bacterial motility analysis
Aqueous motility of wild type Salmonella, flagella knockout Salmonella and VSL#3 was
quantified using fluorescent microscopy. Salmonella strains expressing GFP were grown
in LB until OD600 was in the range 0.6 – 0.8. A 20 μl droplet containing 107 CFU/ml was
added onto a glass slide and covered with a coverslip. Fluorescent microscope images were
captured every 0.141 s for 60 s. Bacterial velocity was analyzed using an automated particle
tracking program, Trackmate in ImageJ (NIH). The average velocity of all the tracks was
calculated per sample. To measure the velocity of VSL#3, the bacteria were inoculated in
serum- and antibiotic-free McCoy’s 5A medium and allowed to recover at 37oC for 1 hour.
The cells were nuclei stained using Hoechst 33342 (NucBlue, Thermo Fisher, Cat #
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R37605). A 20 μl droplet containing 107 CFU/ml was added onto a glass slide and covered
with a coverslip. Fluorescent microscope images were captured every 0.5 s for 60 s. The
average velocity was calculated as described above.

3.4.13 Cryopreservation, histological sectioning, and immunofluorescence staining
To image wild type and flagella knockout Salmonella, bacteria were grown to an OD600
of 0.8. Twenty μl droplets were applied to glass slides and allowed to dry in a biosafety
cabinet approximately six hours.

For histological sectioning, the transwell membranes with intact epithelial and mucus
layers were cut from the inserts and fixed using 10% formalin solution in phosphate buffer
saline for 20 minutes. Fixed membranes were embedded in optimum cutting temperature
(OCT) medium and flash frozen in liquid nitrogen. Using a cryostat (CRYOSTAR NX70,
Thermo Scientific), 30 μm thick cross-sections were cut and collected on ColorMark Plus
glass slides for imaging. Brightfield images were acquired using an EVOS FL Auto
imaging system (Life technologies) and the thickness of the mucus layers were measured
manually using ImageJ (NIH).

For immunofluorescent staining of slides with dried Salmonella, FITC-conjugated antiSalmonella antibody (1:200, ab69253, Abcam) was used. Fluorescent images were
acquired using Zeiss Spinning Disk Axio Observer Z1 microscope (Carl Zeiss) with a CApochromat 63x oil immersion objective and Zen software (Carl Zeiss). For
immunofluorescent staining of histological cross-sections two antibodies were used: FITC-
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conjugated anti-Salmonella antibody and Alexa Fluor 594 conjugated anti-human CD326
(EpCAM) antibody (1:200, Cat # 324228, BioLegend). Both samples on glass slides were
blocked in the blocking solution (1% BSA, 22.52 mg/ml in PBST (PBS + 0.1% Tween20))
for 1 hour at room temperature. Slides were incubated with antibodies diluted in 1% BSA
in PBST for 1 hour at room temperature and washed three times with PBS. Histological
slices were counter-stained with DAPI (1:10,000, D9542, Sigma Aldrich) to identify cell
nuclei. Fluorescent images were acquired using Zeiss Spinning Disk Axio Observer Z1
microscope (Carl Zeiss) with a LD C-Apochromat 40x oil immersion objective and Zen
software (Carl Zeiss).

The stained histological images were analyzed using ImageJ. To quantify Salmonella
density in the mucus gel layer, images were tiled to capture from the top of the mucus to
the bottom of the epithelial layer. Tiled images from three planes deep into the mucus layer
on the glass slides were captured with 10 μm intervals. These three tiled images were
projected on to a single plane. Projected images were uniformly segmented to isolate
bacteria morphologically. The mucus layer height was divided into three regions of equal
height (T: top; C: center; B: bottom). The amount of Salmonella in each region was
measured as the percent area with FITC over the total area using ImageJ.

3.4.14 Statistical analysis
A two-tailed Student’s t-test assuming unequal variances was used for statistical analysis
of pairwise comparison. One-way ANOVA with Bonferroni post hoc test was used for
multiple comparisons. All data are presented as a mean ± standard deviation. Differences
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were considered significant at P < 0.05, with * denoting P < 0.05, and ** denoting P <
0.01.
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Figure 3.1. Biocompatibility of epithelial and mucus gel layers formed on a transwell
membrane. (A) Macroscopic, bottom-view images of the translucent membrane without
mucus (top left) and the opaque mucus layer after gel formation (bottom left). Tiled
microscopic image of the transwell membrane with RFP-expressing HT-29 cells covering
the entire membrane without (top right) and with a mucus layer (bottom right). (B) Side
view of transwell inserts demonstrating sol (left, top) to gel (left, bottom) transition of PSIM
at 0 and 12 hours. Microscopic image of a 20 μm thick histological cross-section of the
transwell membrane covered with HT-29 cell layer (middle) and PSIM gel layer formed
on top (right). (C) A mucus gel layer formed 12 hours after addition of solubilized PSIM
(20 mg/ml) and incubation at 37 °C. (D) Live (Green) and Dead (Red) cell staining of the
epithelial cell layer on a transwell membrane. (E) Quantified area covered by GFP positive
and RFP positive signals showed no significant difference with or without mucus (n = 3).
(F) Confocal microscope image of a DAPI-stained PSIM gel layer (red) with embedded
GFP-expressing Salmonella (green).
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Figure 3.2. Immunological response of epithelial and immune cells to PSIM. (A)
Schematic depiction of the transwell insert placed in 24 multi well plates. HT-29 cells
(blue) were cultured on the apical side of the transwell membrane and cell culture medium
was added to the apical (100 μl) and basolateral (600 μl) side of the cells (w/o mucus).
Reconstituted mucus at 20 mg/ml concentration (brown, 100 μl) layered on top of the
epithelial cells (w mucus). (B) THP-1 cells cultured in 24 multi well plates and cell culture
media (w/o mucus, 100 μl) or reconstituted mucus (w/ mucus, 100 μl) added directly to the
culture medium (600 μl). (C) Mucus increased chemokine (IL-8) secretion from HT-29
cells (*, P < 0.05; n = 3) and (D) no change in cytokine (TNF-α) secretion. Mucus did not
cause a significant change in (E) IL-8 or (F) TNF-α concentration in THP-1 culture medium
(n=3).
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Figure 3.3. Stimulation of HT-29 and THP-1 monocultures by LPS and live bacteria.
(A) IL-8 secretion from HT-29 cells was significantly increased by direct contact with
Salmonella (**, P < 0.01; n = 3). LPS (10 μg/ml) and VSL#3 caused no significant change
in IL-8 secretion. (B) LPS and direct contact with VSL#3 and Salmonella caused IL-8
secretion from THP-1 cells (**, P < 0.01; n = 3). (C) LPS, VSL#3 or Salmonella did not
cause any TNF-α secretion from HT-29 cells. (D) LPS and direct contact with VSL#3 and
Salmonella caused TNF-α secretion from THP-1 cells (*, P < 0.05; **, P < 0.01; n = 3).
(E) Direct contact with VSL#3 caused a change in THP 1 cell morphology (arrows). LPS
and Salmonella did not change THP-1 morphology. Images were taken 12 hours after
adding a stimulant. (F) The number of differentiated THP-1 cells per squared millimeter
was significantly higher with VSl#3 compared to controls (**, P < 0.01; n = 3).
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Figure 3.4. Barrier function of PSIM layer to molecular diffusion. (A) HT-29 cells
(blue) on the apical side of the membrane co-cultured with THP-1 cells (red) in 24 multiwell plates in the absence (top) and presence (bottom) of a PSIM layer (brown). (B,C) The
concentrations of IL-8 (B) and TNF-α (C) from the co-cultures did not change by adding a
PSIM layer, significantly increased by adding LPS to the apical side without mucus, and
was significantly attenuated by adding PSIM layer prior to LPS stimulation (*, P < 0.05; n
= 3).
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Figure 3.5. Barrier function and immune modulation by a PSIM gel layer in response
to VSL#3. (A) VSL#3 transmigrated across the epithelial layer and caused THP-1 cell
differentiation identified by elongated morphologies (arrows). Images were taken 24 hours
after addition of bacteria. (B) The mucus layer significantly reduced the number of
transmigrated VSL#3 bacteria (*, P < 0.05; n = 3). (C-E) The mucus layer significantly
reduced the number of differentiated cells per mm2 (C; **, P < 0.01; n = 3), the
concentration of IL-8 (D; (**, P < 0.01), and the concentration of TNF- α (E; *, P < 0.05)
in the co-culture. (F) A 20 μm thick histological section (Left) stained with EpCAM (Red)
and DAPI (Blue). The PSIM gel layer is auto fluorescent (Blue, arrow). Expanded image
(Right) shows DAPI-stained VSL#3 bacteria embedded at the outer surface of the PSIM
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gel layer (Arrows). (G) Expanded images of the epithelial layer (white star) showing nuclei
and EpCAM staining.
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Figure 3.6. Mucus gel layer is not protective against motile Salmonella. (A) In the
presence of a mucus layer, the number of transmigrated wild type Salmonella increased (*,
P < 0.05; n = 3). Mucus decreased the number of transmigrated flagella knockout (k.o.)
Salmonella (*, P < 0.05). (B) The mean velocity of wild type Salmonella was greater than
VSL#3 and knockout (ΔflhDC) Salmonella (*, P < 0.05; n=5). (C, D) The concentrations
of IL-8 (C) and TNF-α (D) in the co-culture in response to wild type and knockout
Salmonella with and without mucus (*, P < 0.05; n = 3). (E) Fluorescent microscope images
showing the cell bodies (black arrows) and flagella (white arrow) of the wild type (left)
and the knockout (right). Only cell bodies are present for the knockout. (F) A histological
section stained for EPCAM-1 (Red), nuclei (Blue), Salmonella (Green), and the auto
fluorescent PSIM gel layer (Green, arrow). Depth into the mucus layer is indicated as T:
top surface, C: center, B: bottom. (G) Bacterial density in the mucus layer as a function of
depth quantified as the area covered by positive signal from Salmonella stain (**, P < 0.01;
n = 3). Expanded images of the epithelial layer (white star) showing nuclei and EpCAM
staining.
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Figure 3.7. The mucus layer regulates the extent of host-bacterial interactions and the
resultant immune responses. (A) The mucus layer acts as a barrier to VSL#3 and prevents
any immune response. (B) In the absence of a mucus barrier, VSL#3 breach the epithelial
barrier and induce immune responses (TNF-α and IL-8). (C) Despite the presence of a
mucus layer, Salmonella breach the epithelial barrier and induce chemokine (IL-8)
responses from epithelial cells and cytokine (TNF-α) and chemokine (IL-8) responses from
immune cells. (D) In the absence of a mucus layer, Salmonella breach the epithelial barrier
and induce immune responses, similar to in the presence of mucus.
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CHAPTER 4
APPLICATION OF INTESTINAL MUCOSA MODEL TO INVESTIGATE THE
EFFECT OF PROBIOTICS ON PATHOGENIC SALMONELLA INFECTION

4.1 Introduction
Intestinal health is highly dependent on the balance between the microbial species present
in the intestinal tract and the host immune system. Intestinal microbiota plays an important
role in the development of mucosal immunity, maintenance of homeostasis, and mucosal
barrier function. An imbalance in the intestinal microbiota also known as dysbiosis is
linked to several intestinal disorders including inflammatory bowel diseases (IBD)

98-99

.

Dysbiosis can be caused by external factors including abrupt dietary changes, use of
antibiotics, exposure to pathogens, and medical interventions like chemotherapy. The role
of dysbiosis in the initiation and severity of enteropathogenic infection is not completely
understood. The barrier function to pathogens in the intestines is provided by colonization
resistance from commensal microbiota, the biochemical barrier of mucus, tight junctions
in the epithelial cell layer, and inflammation induced immunological response from
resident immune cells

97

. The individual, pairwise, and combined interplay of luminal

bacteria, mucosal barrier, and immune system during enteropathogenic infections are not
well understood.

Salmonella enterica subsp. enterica serovar Typhimurium (S. typhimurium) is a common
enteropathogenic strain causing diarrhea, fever, stomach aches, and can often be fatal
118

117-

. According to CDC estimates, Salmonella bacteria account for over 1.35 million

infections, 26,500 hospitalizations, and 420 deaths every year in The United States alone
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(CDC). The severity of S. typhimurium infections is higher in patients with weakened
immunity (WHO). A prior exposure to S. typhimurium also correlates positively with
incidence of chronic conditions in the intestines such as Inflammatory Bowel Diseases
(IBD)

119-121

. Because of the strong link between S. typhimurium infection and host

immunological response, understanding exact mechanisms involved in these interactions
will help prevent long-term effects of S. typhimurium infections. The role of commensal
microbiota and the protective mucus layer in S. typhimurium infection is not fully
understood.

At the luminal interface, the first point of contact between the ingested pathogens and the
intestines is the secreted mucus layer. The colonic epithelial cell surface is uniformly
covered with a mucus layer approximately 800 um thick and minimizes bacterial contact
with the epithelial cells and tissue resident immune cells 63, 100. Depletion or the improper
barrier function of the colonic mucus layer is linked to bacterial infiltration 103-105, intestinal
inflammation and pathology

47, 49, 101-102

. In healthy condition, the commensal gut

microbiota resides in the outer mucus layer closer to the lumen and mucus close to the
epithelium is devoid of bacteria

63, 100

. The microbiota provides competition against

colonization of ingested pathogens. Dysbiosis of the intestinal microbiota lowers the host
resistance to pathogenic infections and can lead to chronic conditions like IBD

141

. For

example, dysbiosis associated changes in host metabolism and inflammatory environment
in the intestines provided a growth advantage to S. typhimurium over the commensal
microbiota

142

. Treatment with antibiotics caused depletion of commensal microbiota

leading to reduced host resistance to S. typhimurium infection
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143

. The near surface

swimming of S. typhimurium and the attachment to the mucus layer play a role in its
infection ability

106, 122-125

. S. typhimurium can use flagella-driven motility and taxis to

access nutrients at the mucosal surface

144-145

. How S. typhimurium navigate the colonic

mucosal interface in presence of dense microbiota residing in the outer mucus layer is
unknown. A better understanding of the interaction between commensal microbes and S.
typhimurium at the mucosal interface could help uncover mechanisms of enteric
salmonellosis.

After crossing the mucus barrier, pathogens encounter the physical barrier created by the
tight junctions that prevent most bacteria from crossing the epithelial barrier

107-108

. Most

bacteria are detected by binding of common pathogen associated molecular patterns
(PAMPs) to receptors present on the epithelial cell surface called the toll-like receptors
(TLRs) 112-114. Binding of PAMP with TLRs cause activation of downstream pathways like
NF-κB that regulate secretion of signaling and effector molecules called chemokines and
cytokines. In the intestines, epithelial cell derived chemokine interleukin-8 (IL-8) after
detection of bacteria help recruit effector cells like neutrophils to clear the infection 109. In
case of epithelial barrier breakdown, tissue resident dendritic cells and macrophages detect
the bacterial PAMPs using TLRs and secrete IL-8 and pro-inflammatory cytokines
including tumor necrosis factor (TNF-α). TNF-α and IL-8 are pro-inflammatory and
commonly upregulated in IBD patients

115-116

. Identifying the source of these pro-

inflammatory molecules during infection or inflammation can be useful for targeted
therapy in chronic inflammatory disorders including IBD 146-147.
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Recently, probiotics have been considered as potential mainstream therapeutics for chronic
intestinal disorders

148-149

. This transition has shown significant success in clinical trials

and research performed in animals as well as experimental models

150-152

. Apart from

chronic conditions, probiotics have been tested in the treatment of acute pathogenic
infections both as a treatment as well as a prophylactic. Introducing a defined set of
microbes into mice provided a strong resistance against S. typhimurium infection and
reduced pathogenic load in feces 153. For conditions such as recurrent pouchitits, VSL#3 is
being used as a recommended therapy and is shown effective as a primary prevention
measure

154

. VSL#3 is a commercial probiotic mix containing eight bacterial strains

(namely Streptococcus thermophilus, Bifidobacterium breve, B. longum, B. infantis,
Lactobacillus acidophilus, L. plantarum, L. paracasei, and L. delbrueckii subsp.
Bulgaricus). VSL#3 was shown effective in mitigating pathogenic burden and proinflammatory effects caused by Campylobacter jejuni infections in mice 155. VSL#3 showed
a protective effect when administered before inducing inflammation (prophylactic) 156 but
had no healing effect when administered after inducing inflammation (treatment) 157.

Probiotic bacteria induce these protective effects in the host by several mechanisms. These
mechanisms may include competitive growth inhibition of pathogenic bacteria by nutrient
sequestration or production of compounds such as bacteriocins that inhibit the growth of
specific bacteria. It is critical that the probiotics once ingested, effectively colonize the
gastro-intestinal tract, and accumulate there in significant numbers to provide a tangible
probiotic effect. There is a direct correlation between longer colonization times and high
effectiveness of probiotic bacteria 158. Therefore, continual ingestion of probiotics may be
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required for sustained impact on the host. An understanding of the optimum cell number
required to impart the probiotic effect would improve the dosage strategies.

Post colonization probiotic bacteria impart several health benefits to the diseased host. For
example, enhancing epithelial barrier function (ref), modulating epithelial cytokine
secretion into an anti-inflammatory dominant profile (ref), altering mucus production (ref),
and modifying the innate and systemic immune responses

159

. However, it is not well

understood if the direct contact of the probiotic bacteria with the epithelial cells is essential
or they can impart some probiotic effect via secretory mechanisms. Since mucus layer coats
the epithelium, it is critical to evaluate the role of mucus barrier in mediating the effects of
probiotics on the host. The complexity of the intestinal microenvironment with
continuously evolving luminal environment, diverse microbiota and high prevalence of
immune cells make it difficult to parse out bacteria-mucus-host cell interactions in vivo.
In vitro investigations into the bacteria-epithelial interactions are limited due to the poor
mucus secretion and non-uniform coverage in the cellular models commonly used as
intestinal epithelium. Recent advances using primary colonic cells combined with airliquid interface and gut-on-a-chip microfluidic culture methods achieved significantly
thicker mucus layer compared to cell lines 133-134. For non-mucus secreting cell line based
models, porcine mucus is a good alternative for rarely available human mucus

16-17, 34-35

.

We have developed a method to extract porcine small intestinal mucus (PSIM) that retained
the functions of native intestinal mucus

138

. Subsequently, we developed an intestinal

mucosa model including a mucus gel matrix on top of the epithelium that enabled coculture with live bacteria and immune cells 160. The intestinal mucosa model consists of all
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three components (structural mucus gel matrix, epithelial layer, and innate immune cells)
that captures the essential complexities of the mucosal layer in the intestine.

Here, we use the intestinal mucosa model

160

to quantify the role of mucus and epithelial

barrier in regulating the host innate immune responses to probiotic and pathogenic bacteria.
In case of a pathogenic infection, investigating a range of an effective ratio of probiotic to
pathogen that could prevent the growth of the pathogen can help dictate the dosage and the
duration of probiotic intake. To investigate if probiotic mixture VSL#3 can prevent
pathogenic S. typhimurium growth, different mixing ratios were co-cultured and S.
typhimurium growth was quantified using fluorescent spectroscopy. The co-cultures were
added to independently cultured epithelial and innate immune cells to quantify the amount
of pro-inflammatory chemokine and cytokine by enzyme-linked immunosorbent assay
(ELISA). The intestinal mucosa model was used to test the hypothesis that S. typhimurium
could escape any inhibitory or anti-inflammatory effects exerted by VSL#3 in the presence
of mucus. In the mucosa model, a selectively permeable mucus gel matrix formed closely
attached to the epithelium that enabled the investigation into the role of mucus barrier on
the interactions of cocultured bacteria with epithelial cells. Additionally, the mucosa model
provided easy access to the culture medium for quantification of immunological responses
from human epithelial and immune cell cocultures. Bacterial penetration across the
epithelial barrier was quantified using fluorescent confocal microscopy of the transwell
membranes that support the epithelial layers. Mechanistic understanding of the interactions
of pathogenic and probiotic bacteria with mucus, epithelial cell layer and immune cells
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independently as well as in co-culture will help improve the probiotic formulations and
dosage strategies for intestinal diseases.

4.2 Results
4.2.1 VSL#3 suppresses the growth of S. typhimurium in co-culture.
In co-culture, the growth of S. typhimurium was affected by the initial density of VSL#3
(Figure 1). When S. typhimurium were cultured alone, the time to maximum density
increased with decreasing initial density (Figure 1B, top left). At initial densities of 103,102
and 10, the time to maximum density was 6.8, 9.2 and 11.1 h, respectively. These times to
maximum density did not change with the addition of VSL#3 (Figure 4.1B).

At an equal seeding density, VSL#3 had almost no effect on S. typhimurium growth (Figure
1B, top right, circles) compared to S. typhimurium alone (Figure 4.1B, top left). When the
initial density of VSL#3 was 102 times that of S. typhimurium, the maximum density
reduced (Figure 4.1B, bottom left, circles). The greatest effect on growth was when the
initial density of VSL#3 was 104 times the density of S. typhimurium (Figure 4.1B, bottom
right). This condition almost completely blocked the growth of S. typhimurium. At the
point of maximum density (8 h for an initial S. typhimurium density of 103), the Salmonella
density was reduced to almost zero (**, P < 0.01; Figure 4.1C). The density at the endpoint
(12 h) was also significantly reduced (**; P < 0.01, Figure 4.1D).
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The growth of S. typhimurium was dependent on both the initial density ratio and the
absolute initial density. At a density ratio of 104 and low densities (10 and 105 CFU/well
of S. typhimurium and VSL#3, respectively), there was considerable growth (Figure 4.1B,
bottom left, squares). At the same density ratio but higher overall densities (103 and 107
CFU/well), growth was almost completely suppressed (Figure 4.1B, bottom right, circles).
The different growth responses at these conditions represent four physiological conditions
in the intestinal lumen. (1) All VSL#3 (107 CFU/well; termed V7) represents healthy
commensal microbiota with no pathogens. (2) All S. typhimurium (103 CFU/well; termed
S3) represents a high pathogen load with depleted commensal microbiota. (3) Equal density
(103 VSL#3 and S. typhimurium CFU/well; termed V3S3) represents a high pathogen load
with commensal dysbiosis. (4) Mostly VSL#3 (107 CFU/well VSL#3 and 103 CFU/well S.
typhimurium; termed V7S3) represents a low pathogen load with healthy commensal
microbiota. These four conditions were used for most of the subsequent experiments.

4.2.2 Mucus gel matrix using PSIM match the colonic mucus layer in vivo.
The native mucus barrier is impenetrable to bacteria-sized beads. The mucus gel matrix
formed at different concentration of PSIM (Figure 4.2A) and prevented the bacteria-sized
polystyrene beads are from coming in contact with the epithelial cells (Figure 4.2B). The
mucus gel matrix is impenetrable to bacteria sized beads. At a PSIM concentration of 0.5
mg/ml, fluorescent bacteria-sized beads were in direct contact with the epithelial cell layer.
Increasing the PSIM concentration to 1 mg/ml caused a separation of 40.85 ± 0.7 μm.
Further increase in the PSIM concentration to 2.5 mg/ml caused a separation greater than
100 μm, since the beads were not present in the field of view. A PSIM concentration of 20
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mg/ml matches the overall thickness of the colonic mucus layer in vivo (Figure 4.2C). The
mucus gel matrix formed using solubilized PSIM is structurally stable, closely attached to
the epithelium, and qualitatively resembles the mucus layer structure in vivo (Figure 4.2D).

4.2.3 Presence of VSL#3 alters the host immune responses to S. typhimurium.
VSL#3 affects the S. typhimurium induced pro-inflammatory chemokine and cytokine
secretion from human epithelial and immune cell co-culture. Bacteria were co-cultured in
the mucosal barrier platform to quantify the effect of VSL#3, S. typhimurium and the mixed
bacterial cocultures on the epithelial and immune cell responses (Figure 4.3A). The cocultures were performed with or without mucus barrier added on top of epithelial cell layer.
VSL#3 alone did not induce a chemokine (IL-8) response. Also, IL-8 response was
significantly higher in presence of S. typhimurium alone compared to VSL#3 (**; P < 0.01,
Figure 4.3B). Addition of mucus caused a small increase in IL-8 in presence of S.
typhimurium. When VSL#3 and S. typhimurium mixed at equal proportion were added, IL8 response further increased significantly in the absence of mucus (**; P < 0.01, Figure
4.3B). Similar addition of the bacteria mixed in equal proportions and in presence of mucus
caused a 2-fold increase in IL-8 compared to the absence of mucus. Compared to S.
typhimurium alone, equal density mixture of VSL#3 and S. typhimurium caused an increase
of 2.6-fold in IL-8 when mucus is present. In the absence of mucus this increase is
significantly lower (1.8-fold). Increasing the ratio of VSL#3:S. typhimurium to 104:1
reduced the IL-8 amount 10-fold in the absence of mucus but only 3-fold reduction was
seen in the presence of mucus. In the absence of mucus, the IL-8 amount under this
condition was equal to the amount of IL-8 induced by VSL#3 alone. These results suggest
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that VSL#3 at high density ratio of 104:1 significantly suppress the IL-8 response and this
anti-inflammatory effect is stronger in the absence of mucus barrier. Similar to IL-8, coculture of VSL#3 alone did not cause TNF-α production in the mucosal barrier platform.
Addition of S. typhimurium alone caused a 6-fold increase in TNF-α in the absence of
mucus and a 10-fold increase in the presence of mucus (**; P < 0.01, Figure 4.3C) when
compared to VSL#3 alone. Presence of mucus caused a 2-fold increase in TNF-α caused by
S. typhimurium alone. Adding VSL#3 and S. typhimurium in equal ratio caused a significant
increase in TNF-α without mucus but did not have any effect in presence of mucus.
Increasing the ratio of VSL#3:S. typhimurium to 104:1 caused a significant reduction in
TNF-α. As seen with IL-8 response, VSL#3 completely suppressed the TNF-α production
in the absence of mucus. The presence of mucus caused a 2-fold increase in the TNF-α
secretion suggesting that presence of mucus promotes a pro-inflammatory response in
presence of S. typhimurium.

4.2.4 More S. typhimurium cross the epithelial layer in presence of the mucus gel
matrix.
Higher number of S. typhimurium crossed the epithelial layer in presence mucus gel matrix.
Fluorescent confocal microscopy was used to quantify the number of S. typhimurium that
have crossed the epithelial layer (Figure 4.4A). In presence of mucus gel matrix, addition
of S. typhimurium alone increased the number of bacteria by 2.5-fold compared to epithelial
layer only (*; P < 0.05, Figure 4.4B). Compared to S. typhimurium alone, equal density
mixture of VSL#3 and S. typhimurium caused an increase of 4-fold in IL-8 when mucus is
present (**; P < 0.01, Figure 4B). In the absence of mucus this increase in the number of
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S. typhimurium is significantly lower (1.9-fold). Increasing the ratio of VSL#3:S.
typhimurium to 104:1 prevented S. typhimurium completely and no bacteria were found on
the membrane in the absence of mucus. On the other hand, presence of mucus significantly
increased the number of S. typhimurium present on the transwell membrane compared to
without mucus (*; P < 0.05, Figure 4.4B). The results show that increase in the cytokine
and chemokine response is linked to higher migration of S. typhimurium across the mucosal
barrier.

4.2.5 Epithelial and immune cell responses vary depending on the bacterial stimuli.
To parse out the individual contributions of epithelial and immune cells to the responses
discussed above, bacteria were co-cultured with individual cultures of HT-29 and THP-1
cells (Figure 4.5A). Bacteria were introduced to the cultures in the same schemes as
discussed with the mucosal barrier model. VSL#3 alone did not cause IL-8 secretion from
the HT-29 cells. S. typhimurium alone caused a 17-fold increase in IL-8 secretion from HT29 cells (**; P < 0.01, Figure 4.5B). Adding VSL#3 and S. typhimurium in equal ratio
increased the IL-8 secretion 43-fold compared to VSL#3 alone. Further increasing the ratio
of VSL#3:S. typhimurium to 104:1 caused a significant reduction as the level of IL-8 was
similar to the level observed with VSL#3 alone. HT-29 cells did not secrete TNF-α in
response to any configuration of bacteria (Figure 4.5C). Compared to HT-29 cells, a
reverse trend in IL-8 secretion from THP-1 cells was observed. VSL#3 alone caused a
significantly higher IL-8 secretion from THP-1 cells compared to S. typhimurium or any
combination of VSL#3 and S. typhimurium mixtures. S. typhimurium alone caused a 3-fold
reduction in IL-8 secretion from THP-1 cells compared to VSL#3 alone. Equal ratio of

85

VSL#3 and S. typhimurium had a similar effect, and there was no difference compared to
S. typhimurium alone. Increasing the ratio of VSL#3:S. typhimurium to 104:1 caused a
significant increase in IL-8 secretion from THP-1 cells compared to VSL#3 alone (*; P <
0.05, Figure 4.5D). Similarly, the TNF-α production from THP-1 cells was highest in
response to VSL#3 alone. Presence of S. typhimurium significantly suppressed the TNF-α
response from THP-1 cells (**; P < 0.01, Figure 4.5E).

4.3 Discussion
In this study, we investigated the role of dysbiosis in pathogenic infection by coculturing
pathogenic S. typhimurium SL1344 with a mixture of eight bacteria (VSL#3). We found
that relative ratios of VSL#3 and S. typhimurium in the lumen dictate the effectiveness of
VSL#3 in suppressing pathogenic infection and host inflammatory response. VSL#3 was
most effective in suppressing S. typhimurium growth when the number of VSL#3 exceeded
that of S. typhimurium by a factor of 104 or more. The bacteria present in VSL#3 represent
the members of commensal microbiota in healthy humans. The competitive growth
inhibition of S. typhimurium by VSL#3 present at high numbers effectively demonstrates
how the species of commensal microbiota provide resistance to pathogens in vivo.

Dysbiosis of the intestinal microbiota lowers the host resistance to pathogenic colonization
and infections. Indeed, when the number of VSL#3 and S. typhimurium in the coculture
were equal, no significant reduction in S. typhimurium growth was seen. Another factor
that affected S. typhimurium growth was the initial number of S. typhimurium irrespective
of the VSL#3 to S. typhimurium ratio. The results suggest that if a sufficient number of S.
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typhimurium are present at the site of infection, the commensal microbiota may not be
effective in preventing infection. Therefore, the factors including ingestion in large
numbers through food or an imbalance in the commensal microbiota provide a growth
advantage to S. typhimurium and may promote its infection ability. For example, such
imbalance in the commensal microbiota may be induced by broad-spectrum antibiotic
treatment which leaves the host susceptible to virulent pathogens like S. typhimurium 143.

The relative ratios of VSL#3 and S. typhimurium also dictated the pro-inflammatory
chemokine (IL-8) response from human epithelial cells. The reduction in IL-8 was most
effective at the ratio of 104:1, when the growth of S. typhimurium was completely
suppressed suggesting that inhibition of S. typhimurium growth is key for reducing
inflammation. A coculture of S. typhimurium and VSL#3 at equal numbers significantly
increased IL-8 secretion from epithelial cells compared to S. typhimurium alone. Since
VSL#3 alone did not induce any inflammatory response in epithelial cells, this result
indicates some communication between the bacterial species that leads to a strong proinflammatory response induced by S. typhimurium. A possible explanation is that with
equal numbers, VSL#3 does not inhibit S. typhimurium growth effectively but contributes
to nutrient deprivation. Nutrient deprived conditions can induce a switch to a hypervirulent
phenotype in S. typhimurium 161. Overall, these results show that VSL#3 is protective only
when the ratio of VSL#3 to S. typhimurium is in the order of 104 or higher but can contribute
to depletion of nutrients and therefore a more robust S. typhimurium infection when the
ratio is close to one. Clinically, this could mean that an insufficient dosage of VSL#3 can
lead to side effects and worsen the pathogenic infection causing higher inflammation.
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We have developed an intestinal mucosa model that consists of all three components
(structural mucus gel matrix, epithelial layer, and innate immune cells) required to capture
the essential complexities of the mucosal layer in the intestine. The mucus gel matrix not
only matched the thickness and structure of colonic mucus layer but is also impenetrable
to bacteria sized beads (Figure. 4.2) and non-motile bacteria

160

. The intestinal mucosa

model was used to confirm the hypothesis that mucus gel matrix helps S. typhimurium
escape the competitive growth inhibition and anti-inflammatory effects exerted by VSL#3.
In the absence of mucus, S. typhimurium induced a strong IL-8 and TNF-α secretion which
was significantly suppressed by addition of 104 times higher number of VSL#3. However,
in the presence of mucus, VSL#3 failed to suppress S. typhimurium induced IL-8 and TNFα secretion. Combined, these results show that the protective effect of VSL#3 in limiting S.
typhimurium growth and suppressing inflammation is limited to the luminal interface of
mucus. We have shown that the non-motile bacteria in VSL#3 does not penetrate the mucus
gel matrix and accumulate at the mucus interface

160

. On the contrary, the presence of

mucus increased the penetration of motile S. typhimurium across the intestinal barrier. The
increase in transmigration of S. typhimurium in the presence of mucus is flagella dependent
since the strain of S. typhimurium with a flagella-knockout gene did not penetrate the
intestinal barrier. Therefore, the limited migration of VSL#3 and preferential taxis of S.
typhimurium across the mucus layer enables S. typhimurium to cause intestinal infection
and inflammation.
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A similar scenario happens in vivo where most of the commensal microbiota in the colon
reside in the outer mucus layer closer to the lumen and the mucus close to the epithelium
is devoid of bacteria. The mucus layer and commensal microbiota combined must therefore
provide protection from pathogens. Despite the presence of commensal microbiota in the
outer mucus layer and the strong barrier effect of the inner mucus layer, S. typhimurium is
highly successful at infecting the underlying epithelium. This suggests that in the intestinal
mucosa of a host, motile S. typhimurium use the mucus layer to its advantage and escape
competition from the microbiota. In this regard, the use of ‘motile probiotics’ that can
effectively navigate the mucus layer and compete with motile pathogens can be explored.
An example of a motile probiotic is Escherichia coli strain Nissle 1917 (EcN) that possess
flagella162, is antagonistic against pathogens163, has been safely administered in humans 164165

, and can be genetically engineered to develop safe and effective therapy against motile

enteric pathogens

166

. These motile probiotics would not only cause growth inhibition at

the luminal mucus interface but also compete for nutrients and antagonize the pathogens
throughout the mucus gel matrix. Using the intestinal mucosa model, future coculture
studies can be performed to systematically investigate the utility of motile probiotics in
preventing infections caused by pathogens that overcome the mucus barrier.

Clinical use of probiotics targeted towards protection against pathogen invasion and
intestinal inflammation is on the rise

167

. In vivo studies have shown mixed results for

protective effects of VSL#3 on mucosal barrier healing. VSL#3 showed a protective effect
when administered before inducing inflammation (prophylactic)

156

but had no healing

effect when administered after inducing inflammation (treatment) 157. The results presented
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here show that the prophylactic effect of VSL#3 against S. typhimurium infection can be
negated in the presence of mucus. Additionally, clinical benefit can be achieved by a high
dosage routine of VSL#3 enabling robust colonization and growth in the intestines to
outnumber the pathogens and prevent pathogenic growth. This strategy can be most
effective in patients with pre-existing intestinal conditions like Ulcerative colitis since the
mucus layer is either very thin or absent in the lesion areas.

With the rise in antibiotic resistant pathogens due to rampant use of antibiotics, the use of
probiotics can be a successful alternative in preventing food poisoning from common
pathogens. This study provides preliminary proof of the use of VSL#3 as a prophylactic
and could guide the dosing strategies for its use in preventing conditions like traveler’s
diarrhea. About 55% of people traveling from developed countries to developing countries
develop acute diarrhea

168-169

. Therefore, development of general prophylactic treatments

against diarrhea causing pathogens in the form of probiotics are required. In this regard,
the intestinal mucosa model presented here served as an effective tool to test probiotic
efficacy against S. typhimurium infection. The modular nature of this model allowed us to
parse out individual and synergistic interactions of bacteria amongst themselves and with
the host mucosal interface. The platform is amenable to most common characterization
methods including histology, immunostaining, confocal microscopy, and immunological
assays like ELSIA. Most results presented here are only feasible by combining the barrier
components of the mucosal layer including mucus gel matrix, epithelial layer, and innate
immune cells. A mechanistic understanding of how all these components interact in the
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intestinal milieu will help advance therapeutic discovery and treatment for common
intestinal infections and chronic diseases like IBD.

4.4 Materials and Methods
All chemicals and supplies were purchased from Fisher Scientific and Sigma Aldrich
unless otherwise specified.

4.4.1 Mammalian cell culture
HT-29 (ATCC, HTB-38) adherent cells were cultured in McCoy’s 5A medium (Sigma
Aldrich) supplemented with 2.2 g/L sodium bicarbonate. THP-1 (ATCC, TIB-202)
suspension cells were cultured in RPMI-1640 medium (containing 0.05 mM βMercaptoethanol). All media were supplemented with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin and referred to as complete medium in the methods. Cells were
maintained in a 37 oC humidified incubator with 5% CO2.

4.4.2 Solubilized PSIM preparation
PSIM was extracted, sterilized, and prepared for cell culture as described before

138, 160

.

Briefly, intact small intestine tubules were cut into 2-meter lengths and rinsed with water
to eliminate food particles from the lumen. The tubules were drained gently, and the lumen
was filled with 350 ml of 0.01 M NaOH. The ends of the tubules were tied and incubated
for 24 hours at 4 oC. After incubation, the solubilized material was drained by squeezing
and collected. The extract was subjected to centrifugation at 20,000 x g (Thermo Scientific)
at 4 oC for 2 hours to remove insoluble debris. The supernatant was collected without
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disturbing the precipitate. The clear supernatant was subjected to sol-gel transition by
adjusting the pH to 4 using 2 M HCl. The aggregates formed at pH 4 were subjected to
centrifugation at 200 x g for 15 minutes and resolubilized in sterile DI water by adjusting
the pH value to 8. The solution was passed through a 40 μm strainer and subjected to
dialysis using a membrane with molecular size cut-off equal to 14 kDa. The dialyzed
mucus extract was sterilized by adding 1% (v/v) chloroform under constant stirring at 4 ºC
for 72 hours. The solution (30 ml aliquots) was transferred to 50 ml conical polypropylene
tubes, frozen to -80 oC, and freeze dried (Labconco Freezone 2.5 L freeze dry system). The
freeze-dried mucus was reconstituted aseptically in serum- and antibiotic-free McCoy’s
5A medium. The solutions were sterilized in 15 ml polypropylene tubes by adding 10%
chloroform and allowing to sit at 4 oC for 24 hours without shaking. The chloroform
solution formed a distinct layer at the bottom and mucus solutions were collected without
disturbing the interface under aseptic conditions. The solutions were aliquoted in 1.5 ml
polypropylene tubes and stored at -80 oC until use.

4.4.3 VSL#3 and S. typhimurium bacteria culture
Probiotic VSL#3 bacteria were acquired from a commercial source (VSL Pharmaceuticals,
Inc.) and stored at 4 oC until use. For co-culture experiments, the freeze-dried bacteria were
aseptically reconstituted in serum- and antibiotic- free McCoy’s 5A medium at a cell
density of 1010 CFU/ml. Bacterial cells were incubated at 37 oC for 1 hour to recover. After
1 hour, the cell density was diluted to required cell density by serial dilution.
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Wild type S. typhimurium strain SL1344 was used for live motile bacterial experiments.
For experiments, frozen stocks of the S. typhimurium strains were inoculated in LB medium
and grown overnight at 37 oC. Small amount of overnight culture was inoculated in fresh
LB medium and allowed to grow to a density of 4 x 108 CFU/ml and used for further
experiments. To prepare bacteria for transwell co-culture experiments, bacteria culture was
subjected to centrifugation at 2500 x g for 10 minutes. The bacterial cell pellet was washed
three times with PBS by gentle pipetting multiple times and repeating the centrifugation
step in between. Final pellet was reconstituted in serum- and antibiotic-free McCoy’s 5A
medium and the required cell density was adjusted by serial dilution.

4.4.4 HT-29 cell seeding and culture in transwells
For transwell assays, HT-29 cells were detached from culture flasks using trypsin and
seeded at a density of 105 cells per insert in 3 μm pore size polycarbonate membrane
transwell inserts (CLS3415, Corning). Inserts were cultured for 7 days in 24 well plates in
complete McCoy’s medium. The culture medium was changed 24 hours after cell seeding
and every 48 hours after that. After day 7, the culture medium was aspirated from the
transwell inserts. The inserts were washed three times with PBS on both the apical and
basolateral sides. To check for incomplete cell coverage, inserts were filled with 250 μl of
PBS and the change in liquid level was checked for 5 minutes. The inserts with no change
in liquid level were used for further experiments. To check for coverage microscopically,
inserts were seeded with RFP-expressing HT-29 cells. After 7 days of culture, the inserts
were imaged using EVOS FL Auto imaging system (Life technologies). Images captured
using a 10x objective were tiled using in-built EVOS software.
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4.4.5 Mucus gel matrix formation on HT-29 cell surface and mucosal barrier platform
setup
Epithelial cells were grown on transwell inserts and checked for coverage and leakage
using PBS as described above. Mucus layers was formed by adding 100 μl of sterile PSIM
(20 mg/ml) and incubating at 37 oC for 12 hours. For controls without mucus, 100 μl serumand antibiotic-free McCoy’s 5A medium was added to the apical side of the inserts. In
cultures of THP-1 cells, the medium was removed by centrifugation and the cells were
washed with PBS three times. The cell pellet was suspended in serum- and antibiotic-free
McCoy’s 5A medium. The medium in the basolateral side of the transwell inserts was
replaced with 600 μl of THP-1 cell suspension at a density of 105 cells/well. Manufacturers
protocol was followed to quantify human IL-8 (Cat # DY 208) and human TNF-α (Cat #
DY 210) concentrations using DuoSet ELISA assay kit (R&D Systems). Assays were
calibrated to the standard curve created for serially diluted IL-8 and TNF-α standard
solutions on each plate per assay.

4.4.6 Stimulation of HT-29 and THP-1 monocultures with VSL#3 and S. typhimurium
Twenty-four well tissue culture treated plates were seeded with 105 HT-29 cells per well
and cultured for 4 days with a media change every day. After 4 days, the cells were washed
with PBS three times and replaced with 450 μl serum- and antibiotic-free McCoy’s
medium. To each well, 50 μl of medium was added that contained bacterial endotoxin
lipopolysaccharide (LPS, 10 μg/ml) from Escherichia coli O55:B5 (Cat # L6529), VSL#3
(2 x 109 CFU/ml), or S. typhimurium (2 x 105 CFU/ml). Media alone (50 μl) was added to
control wells. After 12 hours of incubation at 37 oC, the media were collected from three
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independent experimental conditions. Human IL-8 and TNF-α concentrations were
quantified using ELISA assays.

Using a similar procedure as above, 105 THP-1 cells were suspended in serum- and
antibiotic-free medium (600 μl); seeded into 24 well plates; and stimulated with 50 μl LPS
(10 μg/ml), VSL#3 (2 x 109 CFU/ml), and S. typhimurium (2 x 105 CFU/ml). After 12
hours of incubation at 37 oC, the medium was collected and the concentrations of human
IL-8 and TNF-α were quantified using ELISA assays. Results from three independent
experiments were used analysis.

4.4.7 VSL#3 interaction with in vitro mucosal lining model
The in vitro mucosal lining model was challenged by adding 50 μl per well of VSL#3
culture (2 x 109 CFU/ml) to the apical side of the transwell inserts. After 12 hours of
incubation at 37 oC, the transwell inserts were removed and brightfield images of the
bottom well containing THP-1 cells were captured using EVOS FL Auto imaging system
(Life technologies). The contrast of the images was uniformly enhanced. Post-imaging, the
medium was collected from the bottom well. Half of the medium was used for
quantification of human IL-8 and human TNF-α with ELISA. Data was analyzed for three
independent experiments.

4.4.8 S. typhimurium interaction with mucosal barrier model
The in vitro mucosal lining model was challenged by adding 50 μl per well of GFP-labeled
S. typhimurium (2 x 105 CFU/ml) to the apical side of the transwell inserts. After 12 hours
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of incubation at 37 oC, the transwell inserts were removed. The medium was collected and
used for quantification of human IL-8 and human TNF-α with ELISA. Measurements and
analysis were performed for three independently conducted experiments.

4.4.9 VSL#3 and S. typhimurium coculture interaction with mucosal barrier model
The in vitro mucosal lining model was challenged by adding 50 μl per well of GFP-labeled
S. typhimurium and untagged VSL#3 at specified density ratios to the apical side of the
transwell inserts. After 12 hours of incubation at 37 oC, the transwell inserts were removed.
The medium was collected and used for quantification of human IL-8 and human TNF-α
with ELISA. Measurements and analysis were performed for three independently
conducted experiments.

4.4.10 Cryopreservation, sectioning, and immunohistochemistry
To image and wild type and flagella knockout S. typhimurium, bacteria were grown to an
OD600 of 0.8. Twenty μl droplets were applied to glass slides and allowed to dry in a
biosafety cabinet for approximately six hours.

For histological sectioning, the transwell membranes with intact epithelial and mucus
layers were cut from the inserts and fixed using 10% formalin solution in phosphate buffer
saline for 20 minutes. Fixed membranes were embedded in optimum cutting temperature
(OCT) medium and flash frozen in liquid nitrogen. Using a cryostat (CRYOSTAR NX70,
Thermo Scientific), 30 μm thick cross-sections were cut and collected on Color Mark Plus
glass slides for imaging. Brightfield images were acquired using an EVOS FL Auto
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imaging system (Life technologies) and the thickness of the mucus layers were measured
manually using ImageJ (NIH). Images from three independent samples were used for
measuring the thickness.

For immunofluorescent staining of histological cross-sections two antibodies were used:
FITC-conjugated anti-S. typhimurium antibody and Alexa Fluor 594 conjugated antihuman CD326 (EpCAM) antibody (1:200, Cat # 324228, Bio Legend). Sections on the
glass slides were blocked in the blocking solution (1% BSA, 22.52 mg/ml in PBST (PBS
+ 0.1% Tween20)) for 1 hour at room temperature. Slides were incubated with antibodies
diluted in 1% BSA in PBST for 1 hour at room temperature and washed three times with
PBS. Histological slices were counter-stained with DAPI (1:10,000, D9542, Sigma
Aldrich) to identify cell nuclei. Fluorescent images were acquired using Zeiss Spinning
Disk Axio Observer Z1 microscope (Carl Zeiss) with a LD C-Apochromat 40x oil
immersion objective and Zen software (Carl Zeiss).

The stained histological images were analyzed using ImageJ. To quantify S. typhimurium
density in the mucus gel layer, images were tiled to capture from the top of the mucus to
the bottom of the epithelial layer. Tiled images from three planes deep into the mucus layer
on the glass slides were captured with 10 μm intervals. These three tiled images were
projected on to a single plane. Projected images were uniformly segmented to isolate
bacteria morphologically. The mucus layer height was divided into three regions of equal
height (T: top; C: center; B: bottom). Images were collected from three independent
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samples. The amount of S. typhimurium in each region was measured as the percent area
with FITC over the total area using ImageJ.

4.4.11 Statistical analysis
A two-tailed Student’s t-test assuming unequal variances was used for statistical analysis
of pairwise comparison. One-way ANOVA with Tukey post hoc test was used for multiple
comparisons. All data are presented as a mean ± standard deviation for three or more
independent experimental conditions. Differences were considered significant at P < 0.05,
with * denoting P < 0.05, and ** denoting P < 0.01.
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Figure 4.1. S. typhimurium growth in co-culture with VSL#3. (A) Schematic of the coculture of untagged VSL#3 and GFP-expressing S. typhimurium in 96 multi-well plates and
quantification of growth by fluorescence spectroscopy in a multi-well plate reader. (B)
Growth curves of S. typhimurium with changing initial seeding density. (C) Cell density
(RFU) at 8 hours where the peak was observed for all growth curves (**, P < 0.01; n = 3).
(D) Cell density (RFU) at the end point of 12 hours used for all the co-culture studies with
human epithelial and immune cells (**, P < 0.01; n = 3). (S, V denotes and S. typhimurium,
VSL#3, and Numerals 3, 5, 7 denotes 103, 105, 107 CFU/well of the 96 multi-well plate).
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Figure 4.2. Mucus gel layer formation matching the thickness of colonic mucus. (A)
Schematic of the mucus gel layer formation on top of HT-29 epithelial cells growing on
transwell membrane. A 100 μl of PSIM at known concentrations were added on the apical
side of the transwell inserts containing the HT-29 cell layers and cultured for 12 hours at
37oC to form the mucus gel matrix. (B) Confocal images of red fluorescent polystyrene
beads added after mucus gel layer formation on HT-29 cells (Blue) at different PSIM
concentration 0.5, 1, and 2 mg/ml. Top row shows the x-y projection and the bottom row
shows the z-projection. Dotted line represents the plane of highest intensity of the
fluorescent beads. (C) Table containing the average thicknesses of the mucus gel layer
using PSIM160 at different concentrations compared with the average mucus layer thickness
of colonic mucus layer in vivo58. (D) Mucus gel layer formed at PSIM concentration of 20
mg/ml matched the thickness and structure of the colonic mucus layer in vivo. Dotted line
represents the porous transwell membrane location.
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Figure 4.3. Chemokine (IL-8) and cytokine (TNF-α) levels in the mucosal barrier
model. (A) The infection scheme for introducing VSL#3 and S. typhimurium individually
and cocultured into the mucosal barrier model with or without mucus gel matrix. IL-8 and
TNF-α were quantified in the media collected from the basolateral compartment after 12
hours of culture. Notations denote V7 = 107 CFU/insert of VSL#3, S3 = 103 CFU/insert,
V3S3 = 103 CFU/insert of VSL#3 + 103 CFU/insert of S. typhimurium, and V7S3 = 107
CFU/insert of VSL#3 + 103 CFU/insert of S. typhimurium added apically (100 μl) and
cultured for 12 hours. Concentration of (B) IL-8 and (C) TNF-α from the mucosal barrier
platform in response to stimulation with different bacterial cell densities after 12 hours of
culture (*, P < 0.05; **, P < 0.01; n = 3).
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Figure 4.4. Quantification of S. typhimurium crossing the epithelial barrier. (A) S.
typhimurium (Green) that have crossed the epithelial (Blue) barrier visualized using
confocal microscopy. Black arrows indicate the pores in the transwell membrane and white
arrows indicate S. typhimurium. (B) The number of S. typhimurium quantified by manual
counting individual bacteria (*, P < 0.05; **, P < 0.01; n = 3).
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Figure 4.5. Chemokine (IL-8) and cytokine (TNF-α) levels from stimulated epithelial
(HT-29) and immune (THP-1) cells. (A) The infection scheme for introducing VSL#3 and
S. typhimurium individually and cocultured into 24 well plates with adherent HT-29 cells
and suspended THP-1 cells. IL-8 and TNF-α were quantified in the media collected after
12 hours of culture. Concentration of (B) IL-8 and (C) TNF-α from the HT-29 cells in
response to stimulation with different bacterial cell densities (*, P < 0.05; **, P < 0.01; n
= 3). Concentration of (D) IL-8 and (E) TNF-α from the THP-1 cells in response to
stimulation with different bacterial cell densities (*, P < 0.05; **, P < 0.01; n = 3).
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Figure 4.6. S. typhimurium utilize the mucus barrier to escape competitive growth
inhibition from commensal bacteria and cause intestinal infection. (A) Non-motile
probiotic bacteria (VSL#3) present at higher cell density compared to pathogen (S.
typhimurium) effectively prevent S. typhimurium growth. The mucus interface is
impenetrable to non-motile VSL#3, but hyper-motile S. typhimurium preferentially
colonize the mucus layer. The escape mechanism is flagella dependent and enhance the
infection ability of S. typhimurium. The epithelial barrier and innate immune cells
(Macrophages and Dendritic cells) are the first responders in the inflammatory responses
to pathogenic infection. (B) Fluorescent confocal microscope images showing epithelial
cell adhesion molecule-1 localization (Red, arrow), S. typhimurium distribution (Green,
arrows), and Epithelial cell nuclei with mucus gel matrix (Blue, arrows). (C) Fluorescent
confocal microscope image of all three channels overlaid showing S. typhimurium
distribution throughout the mucus gel matrix and infecting the epithelial cells.

104

CHAPTER 5
FUTURE APPLICATIONS AND CONCLUSION
5.1 Development of a probiotic encapsulation and delivery vehicle using PSIM
The scalable mucus extraction process established in this work can enable development of
delivery vehicles for orally ingested therapies. The intrinsic properties of mucus make this
biomaterial an ideal candidate for oral delivery. We hypothesize that the intact sol-gel
transition of mucus will protect a therapeutic compound or live probiotic bacteria from the
harsh acidic environment of the stomach. We tested this concept by adding a droplet of
PSIM (20 mg/ml) at pH 7 on top of a droplet of 20 mM HEPES buffer at pH 4 (Figure 5.1).
Fluorescently labeled (Cy5) Sambucus nigra agglutinin (SNA) lectins were mixed in the
PSIM solution for fluorescence microscopic visualization. A distinct ring of PSIM was
formed with the aggregated PSIM on the outside. No aggregation was observed in the
center of the ring. Cy5 lectin stain was also localized in the aggregated region with slight
diffusion of possibly unbound lectin towards the center of the ring. This test indicates a
feasibility of PSIM bead formation with an aggregated shell that forms a protective barrier
against gastric acid and the desired therapeutic in the core of the bead (Figure 5.2A). We
have demonstrated previously that PSIM is a solution at pH 7 but formed a gel at pH 4 and
undergoes spontaneous sol-gel transition with change in the pH (Figure 5.2B). This
property will be ideal for release of the encapsulated therapeutics in the neutral pH
conditions present in the small and large intestines. To demonstrate the encapsulation,
green, fluorescent polystyrene microbeads were mixed in PSIM (20 mg/ml) at pH 7. The
mixture was gently pipetted into a bath containing 20 mM HEPES buffer at pH 4 forming
a cross-linked spherical bead (Figure 5.2C). Fluorescent confocal microscopy showed
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embedded GFP expressing polystyrene microbeads in the matrix of the PSIM beads (Figure
5.2D). This concept can be applied for encapsulation, gastric protection, and delivery of
probiotic bacteria to the intestines.
To streamline this process a microfluidic platform can be utilized that will enable
encapsulation of the probiotic bacteria in PSIM (pH 7) using a flow focusing channel
containing a buffer solution at pH 4 (Figure 5.2E). After the beads are formed, they will
pass through another flow focusing junction where the beads will be exposed to a buffer
solution at pH 2. The beads can be collected while immersed in the pH 2 buffer solution.
Lyophilization of the beads can be tested for long-term storage of the encapsulated
probiotic bacteria. Further validation will be required to test if the beads are actually
forming core-shell regions. Furthermore, the viability of the encapsulated probiotic
bacteria can be tested by solubilizing the beads in a buffer solution at pH7. PSIM can be
expected for good tolerance in the intestines since the mucin macromolecules are highly
abundant in the lumen. To be clinically applicable, PSIM should be tested for presence of
any endotoxins and other immunostimulatory antigens. Information on the exact
biochemical composition of PSIM can lead to large-scale clinical applications.
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Figure 5.1 PSIM ring formation in low pH. Microscopic images of PSIM droplet (pH 7)
interacting with a 20 mM HEPES buffer droplet (pH 4) and forming a ring with aggregated
mucus at the periphery and PSIM solution in the core.
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Figure 5.2 Conceptual design of core-shell particles of PSIM for probiotic
encapsulation. (A) Schematic of the hypothesized PSIM beads that encapsulate probiotic
bacteria in the core, protects the bacteria from gastric acid and releases the bacteria in the
neutral environment of the intestines by reversible gel to sol transition. (B) Demonstration
of sol (pH 7) to gel (pH 4) transition of PSIM (80 mg/ml) compared to commercially
available porcine gastric mucin (PGM) that does not undergo sol-gel transition in response
to pH change. (C) PSIM bead formation by gently pipetting 10 μl of PSIM (pH 7) into a
bath of 20 mM HEPES buffer (pH 4). (D) GFP expressing polystyrene beads (1 μm size)
embedded in Cy5 lectin stained PSIM gel matrix. (E) Proposed microfluidic device for
streamlining probiotic encapsulation, uniform sized bead formation, and collection of
PSIM beads at pH 2 that is similar to pH in the gastric lumen.
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5.2 Creation of a two-layer mucus barrier relevant to the large intestine mucus
barrier
Large intestines are the biggest reservoir of bacteria in the human body. The mucus layer
protects underlying tissue from coming in direct with the bacteria. The most intriguing
feature of the mucus layer in the large intestine is the structural organization into a twolayer system. The inner layer is tightly bound to the epithelium and is devoid of bacteria.
The outer layer is loosely attached and is colonized by commensal bacteria. The exact
mechanisms of how this structural layering is achieved in vivo are still being discovered.
Consequently, it has been challenging to recreate the two-layer mucus barrier of the large
intestine in vitro. Development of an in vitro model that mimics this essential feature of a
healthy mucus barrier can provide significant insights into the factors that can lead to
pathological conditions of large intestines. We have demonstrated before that PSIM forms
structurally stable layers on top of transwell membranes in Chapter 2. The structure of the
PSIM can be controlled by changing PSIM concentration, addition of multivalent cations,
and changing pH. Since the pH in the intestines is maintained close to neutral, we utilized
the change in PSIM concentration and Ca2+ ion concentration to create multiple layers with
structural differences. Since the inner mucus layer is known to be more cross-linked and
impenetrable to bacteria, we used a combination of high PSIM concentration (100 mg/ml)
and high Ca2+ concentration (100 mM) to create this layer (Figure 5.3A). A 50 µL solution
of PSIM in 20 mM HEPES buffer was added to the apical compartment of a transwell
insert (3 µm pore size) and 100 mM CaCl2 solution in 20mM HEPES buffer was added to
the basolateral compartment of a 24 well plate. After incubation at 37oC in a humidified
incubator for 12 hours, 100 µL solution of PSIM (20 mg/ml) was added on top of the
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preformed mucus layer. After incubation at 37oC in a humidified incubator for 12 hours,
the transwell membranes were carefully separated from the inserts and immersed in 10 %
Formalin solution for 30 minutes. The fixed mucus layers were embedded in optimum
cutting temperature (OCT) matrix and cryo-frozen by immersing in liquid Nitrogen. The
frozen samples were sectioned into 20 µm thick slices using a cryostat. Fluorescently
labeled (Cy5) Sambucus nigra agglutinin (SNA) lectins were mixed in the PSIM solution
prior to gel formation to facilitate imaging after cryo-sectioning. The combination of high
PSIM concentration (100 mg/ml) and gradient of Ca2+ ions from the basolateral
compartment lead to formation of highly cross-linked mucus gel layer (Figure 5.3A). The
gel layer was structurally stable and could be visualized microscopically by fluorescent
microscopy. By adding PSIM solution at low concentration (20 mg/ml) on top of the first
layer formed a structurally distinct outer mucus layer (Figure 5.3B). Fluorescent
microscopy showed a clear interface between the two layers along with difference in the
structure of both layers. The inner layer showed large areas of dense aggregates identified
by bright fluorescence indicating higher density and cross-linking. The outer layer had
branched structure and no bright fluorescent aggregates indicating the absence of Ca2+
induced crosslinking and therefore a loose structure. The results show that the two-layer
structure of mucus barrier present in the large intestine can be captured by using PSIM.
Several challenges remain to make this system more physiological. The transwell platform
does not allow the reduction in the height of the mucus layer formed. The viscoelastic
properties and height of the inner and outer mucus layer needs to be tuned to match the in
vivo properties of the mucus layers. This can be done by 1. Systematic testing of PSIM and
Ca2+ concentrations, 2. Using methods like Particle tracking microrheology to measure the

110

viscoelastic properties of the gel layers formed, and 3. Creating tools to precisely control
the thickness of the gel layers formed while still allowing the apical and basolateral
interactions of PSIM and Ca2+ ions.
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Figure 5.3 Two-layer mucus barrier formation using PSIM. (A) Schematic of the inner
layer formation by using high concentration of PSIM in the apical compartment and high
concentration of Ca2+ ions in the basolateral compartment (Left). After incubation, a
structurally stable mucus gel layer formed (Middle) which was visualized using fluorescent
microscopy (Right). (B) Schematic of the outer layer formation by using low concentration
of PSIM on top of the preformed inner layer in the apical compartment and HEPES buffer
solution without Ca2+ ions in the basolateral compartment (Left). After incubation,
structurally stable mucus gel layers formed (Middle) which were visualized using
fluorescent microscopy (Right).
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5.3 Microfluidic platform for dynamic mucus barrier formation using PSIM
The mucus lining along the gastrointestinal tract is the outermost and largest interface in
the body that protects the epithelium, regulates the selective transport of nutrients, and
maintains symbiosis in presence of microbes (Figure 5.4). Goblet cells constitute about 412% of epithelium in the small intestine and up to 20% in the large intestine, which
correlates with the properties and height of the mucus barrier. In human intestines, the turnover rate of the entire mucus layer is close to 1 hour meaning that the mucus layer is
essentially flowing at a very low rate. The secreted mucin biopolymers regulate barrier
function via in situ biochemical and biophysical interactions with the luminal content that
periodically fluctuates. Mimicking the mucus layer that is constantly replenishing and
dynamically responsive to changes in surrounding environment (pH and ionic
concentration) has not been realized in most commonly used in vitro models of human
intestines. In vitro mucus barrier model that replenishes continually and is responsive to
luminal content can serve as an enabling tool for understanding the interactions and
transport of orally administrated drug compounds as well as bacteria across the protective
mucus barrier in vivo.

To achieve this a simple microfluidic design was developed that enables flow of luminal
content and PSIM in parallel. The microfluidic design was prepared using Adobe Illustrator
software. A single microfluidic channel with Y-shaped inlets and outlets was printed on a
250 μm thick poly-dimethyl siloxane (PDMS) sheet using Graphtec plotter cutter. The
PDMS sheet with the channel was bound onto a glass slide and covered with a thick PDMS
sheet using oxygen plasma treatment for 2 minutes and a platform with multiple channels
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on a single platform was created (Figure 5.5A). The channel layer was covered on top with
a 3 mm thick PDMS layer with the inlet and outlet ports punched prior to oxygen plasma
bonding for 2 minutes. All surfaces must be kept clean by washing in 70 % Ethanol and
allowing the ethanol to air dry without touching the surface. The syringes containing PSIM
or buffer solution were connected to the inlet ports using polypropylene tubing with 1 mm
inner diameter. The flow was controlled using Harvard apparatus syringe pumps. The
channels were filled with 20 mM HEPES buffer at pH 7 before connecting the inlet and
outlet tubing to prevent air bubble formation. The exclusive presence of laminal flow
profile in microfluidic devices prevents mixing and enables the study of diffusion across
the interface between the two phases (Figure 5.5B). The device was tested by flowing a
solution of food coloring dyes (blue and red) at a flow rate of 10 μl/min. A distinct interface
was formed at the center of the main flow channel.

To demonstrate this concept with luminal content and mucus, PSIM in 20 mM HEPES
buffer at a physiological concentration (20 mg/ml) and pH 7 was flown from one inlet and
luminal content (20 mM HEPES buffer) with changing Ca2+ concentrations was flown
from the other at a flow rate of 10 μl/min. We hypothesized that at the interface where the
luminal content came in direct contact with PSIM, a diffusive barrier would form due to
Ca2+ induced aggregation and cross-linking of mucus. Indeed, a visible barrier formed that
changed in real time in response to Ca2+ concentration in the luminal content (Figure 5.6A).
The thickness of the mucus gel layer increased by increasing the Ca2+ concentration in the
luminal compartment (Figure 5.6B). At 5mM Ca2+, mucus gel layer did not form in the
entire channel. Increasing the Ca2+ concentration to 25 mM significantly increased the
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thickness of the layer. Further increase in the Ca2+ concentration to 100 mM caused a 3fold increase in the gel layer thickness compared to 25 mM Ca2+. Increasing gel layer
thickness caused reduction in the diffusion of FITC dextran (20 kDa) (Figure 5.6C). At 5
mM Ca2+ FITC dextran diffused across the interface and there was no difference in the
GFP intensity in the luminal half and the mucus layer. At 25 mM and 100 mM Ca2+ a
significant reduction in GFP intensity was measured in the mucus layer suggesting that the
Ca2+ induced cross-linking of mucus at the interface acts as a barrier for molecular
diffusion. In our preliminary testing, mucus aggregates also formed in the presence of most
physiologically relevant and multivalent cationic species like Mg2+, Zn2+, Fe2+, and Fe3+.
Most of these cations including calcium are present in foods and supplements ingested by
humans on a regular basis. Therefore, the role these cations in the barrier function and
nutrient absorption across the intestinal mucus barrier can be systematically explored using
the microfluidic platform. The ease of imaging will enable systematic characterization of
transport behavior of fluorescently labelled carbohydrates, amino acids, lipids, food grade
nanoparticles, and live bacteria across the mucus barrier while changing pH and ionic
concentrations.

Currently, the microfluidic device requires both the luminal content flow and PSIM to flow
at equal flow velocity for the interface to form at the center of the device. Setting the flow
rate at 10 10 μl/min in both the flow streams also ensured proper clearance of the device
for operation until 1 hour. Under the current operating parameters, the flow velocity is two
orders of magnitude higher than the physiological replenishing rate of mucus (hourly
turnover). However, reducing the flow rate close to the physiological range caused
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accumulation of aggregates, disruption of the gel layer interface and clogging of the device.
Also. It may be ideal to have a stable static mucus barrier and flowing luminal content
which will enable consistent quantification of diffusion across the mucus layer. However,
stopping the mucus flow also leads to accumulation of aggregates, disruption of the gel
layer interface and clogging of the device. One solution for this problem is to optimize the
mucus flow rate as close to physiological as possible without clogging the device for at
least 30 minutes. Matching the flow rate of luminal content with the optimized mucus flow
rate will ensure a uniform interface formation that will also enable consistent measurement
of diffusion across the gel layer formed at the interface. Another solution for this problem
is to quantify the diffusion exclusively in the region of the gel interface. Since the gel
interface once formed remains static irrespective of the flow rates of the luminal content or
the PSIM. This strategy is more feasible for particle of micrometer scale and bacteria but
may not be suitable for small molecule diffusion. Additional work is required in this
direction.
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Figure 5.4 Luminal environment of the intestines is highly complex and dynamically
evolving. Schematic showing the complex environment in the lumen of the intestinal tract
including endogenously secreted gastric acid, bile salts, enzymes, and the resident
microbiota. The lumen is also exposed to exogenous factors such as dietary molecules and
pathogenic bacteria. The continuous secretion of the mucus and peristaltic movement of
the luminal contents help in physically protecting the underlying tissue and clearance of
the harmful luminal content continually.

117

Figure 5.5 Dynamically responsive mucus barrier in a microfluidic platform. (A)
Schematic of the microfluidic device fabrication process. (B) Schematic of the conceptual
flow regimes in the 2-inlet microfluidic device. (C) Digital images of the microfluidic
device in operation, microscopic image of the flow channels and food coloring dye blue
and red forming an interface in the central microfluidic channel.
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Figure 5.6 Regulation of molecular diffusion via PSIM gel formation at the lumenmucus interface. (A) Microscopic images of Ca2+ dependent PSIM gel interface forming
in the central microchannel. (B) Thickness of the gel interface increases with increasing
Ca2+ concentration. (C) Diffusion of FITC dextran (20 kDa) dye is reduced with increasing
gel layer thickness.
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5.4 ‘Intestine mucosal barrier on a chip’ for real time host-microbe interaction
To mimic intestinal physiology, two microfluidic designs were developed to combine a
flow channel for luminal content, a flow channel for replenishing mucus layer and
epithelial cell layer (Figure 5.7). This way bacteria can be cocultured with epithelial cell
surface in presence or absence of mucus layer. Continuous removal of culture medium will
prevent bacterial overgrowth. Due to the planar design of the microfluidic platform,
interactions of bacteria with mucus gel and epithelial cells can be captured in real time.
The devices were designed to specifically include 1. Resident immune cells embedded in
extracellular matrix to mimic the innate immune responses, 2. Endothelial cell layer with
a separate flow channel for capturing transmigration of effector cells into the extracellular
matrix following a chemokine gradient. The devices were developed using a simple and
cost-effective strategy that eliminated the use of microfabrication related instruments and
cost involved.

The microfluidic design was prepared using Adobe Illustrator software. A single
microfluidic channel with Y-shaped inlets and outlets was printed on a 500 μm thick polydimethyl siloxane (PDMS) sheet using Graphtec plotter cutter. The PDMS sheet with the
channel was bound onto a glass slide and covered with a thick PDMS sheet using oxygen
plasma treatment for 2 minutes and a platform with two devices on a single glass slide was
created (Figure 5.8A). In a biosafety cabinet, the PDMS pieces cut out from the sheet were
placed back in their position except the rectangular piece designated for collagen gel layer
formation. Rat tail collagen (Type 1) solution (8 mg/ml) and 10x concentrated cell culture
medium (w/ Phenol red) were placed on ice. The collagen solution and the 10x medium
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were mixed in a proportion of 9-parts collagen and 1-part 10x medium and mixed gently
to prevent any air bubble formation while keep the solution on ice at all times. The mixed
solution (25 μl) was gently pipetted in the vacant rectangular piece making sure that no air
bubble form and the solution is in contact with all the corners. For embedding immune
cells in the collagen gel, the immune cell pellet should be formed by centrifugation and
then resuspended using the collagen-medium solution. Depending on the efficiency of
mixing, the collagen-medium solution will start to turn opaque at room temperature in 510 minutes indicating the collagen gel formation. To speed up the gel formation, the
collagen-medium solution can be incubated in a humidified incubator at 37oC with constant
monitoring of the gel. The gel should not be left for too long at room temperature or 37oC
incubator as the dehydration of gel will affect the sealing of the collagen gel to the top
PDMS and bottom glass surface. After gel formation, the PDMS pieces inserted in the main
channels were gently removed (Figure 5.8B). This layer containing the collagen gel and
the flow channel on the glass slide should not be taken out of the biosafety cabinet to
maintain sterility and should not be exposed to plasma treatment. The channel layer was
covered on top with a 3 mm thick PDMS layer with the inlet and outlet ports punched prior
to oxygen plasma bonding for 2 minutes. While binding ensure the alignment of the inlet
and outlet ports with the channels and are should be taken to not disturb the collagen gel
layer. All surfaces must be kept clean by washing in 70 % Ethanol and allowing the ethanol
to air dry without touching the surface inside a biosafety cabinet. For cell seeding and
culture 200 μl pipet tips were inserted in the inlet and outlet ports and the medium level
was maintained by gravity driven flow (Figure 5.8B). For flow experiments, the syringes
containing cell suspensions, PSIM and cell culture medium solution were connected to the
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inlet ports using polypropylene tubing with 1 mm inner diameter. The flow was controlled
using Harvard apparatus syringe pumps. The channels were filled with cell culture medium
before connecting the inlet and outlet tubing to prevent air bubble formation.

To test the stability of the cell-free collagen layer (Figure 5.9A), gravity-driven flow was
used to perfuse phosphate buffer solution (PBS) containing 1 µg/ml of FITC dextran (20
kDa) and TRITC dextran (155 kDa). The devices were imaged over time for GFP and RFP
fluorescence to quantify the rate of diffusion of these molecules across the collagen gel
layer (Figure 5.9B). FITC dextran diffusion was significantly faster compared to TRITC
dextran over time indicating that the rate of diffusion is size-dependent. Differences in the
rate of diffusion of the two differently sized molecules also suggest that there is no leakage
around the edges of the collagen gel. Additionally, the diffusion appeared to be uniform
along the entire length of the collagen gel. FITC dextran (20 kDa) diffused across the entire
width of the collagen gel reaching close to steady state in 4 hours suggesting that the cells
can be embedded in the collagen gel since the nutrients can easily diffuse across the gel
layer.

Immune (THP-1) cells embedded in the collagen gel under static conditions remained
viable for more than 7 days (Figure 5.10A). The cell culture medium was replaced every
other day. Cell viability was confirmed by blue, fluorescent live cell tracker (Hoechst
33342). Coculture of immune cells with live bacteria was tested by introducing red
fluorescent protein (RFP) expressing E. coli Nissle 1917 strain in the luminal channel.
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Fluorescence microscopy was used to track the growth of bacteria over time confirming
the ability of real time imaging in the microfluidic platform (Figure 5.10B).

To establish the epithelial cell layer, epithelial (HT-29) cells were seeded on one edge of
the gel by seeding 105 cells per device, setting the device vertical so that suspended cells
settle on the collagen gel surface and incubated at 37oC and 5% CO2 in a humidified
incubator. Cell culture medium was changed daily, and coverage of the epithelia cells was
confirmed by brightfield imaging (Figure 5.11A). Epithelial cells covered the entire surface
of the collagen gel in 3-5 days. The cell layer was fixed by perfusing 10% Formalin solution
and incubating at room temperature for 30 minutes. To confirm the formation of tight
epithelial barrier, HT-29 cells were stained with EPCAM-1 (Red) and nuclei (Blue). The
epithelial cells formed a 3D structure with well-defined epithelial cell junctions (Figure
5.11B). To mimic the physiological complexity of intestines, PSIM gel layer was
reconstituted in the main channel along with green fluorescent protein (GFP)-expressing
bacteria suspended in cell culture medium (McCoy’s 5A) supplemented with 20 mM Ca2+.
To demonstrate continuously replenishing luminal content, flow was maintained at 3
μl/min. Calcium induced aggregation created a distinct separation between the epithelial
cell layer and the GFP bacteria flowing across the luminal side (Figure 5.11C top). By
stopping the flow, mucus barrier was disrupted that caused the bacteria to fill the entire
channel and came in direct contact with the epithelial cells (Figure 5.11C bottom).

Similarly, to establish endothelial cell layer after epithelial cell attachment, endothelial
(HUVEC) were seeded on the other edge of the gel by seeding 105 cells per device, setting
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the device vertical so that suspended cells settle on the collagen gel surface and incubated
at 37oC and 5% CO2 in a humidified incubator. Collagen gel successfully created a partition
between the top Y-inlet channel and the straight channel on the bottom (Figure 5.12A).
Epithelial cells formed a uniform layer on the top edge of the collagen layer and expressed
epithelial cell adhesion molecule - 1 (EPCAM-1) after 3 days of culture (Figure 5.12B).
Endothelial cells formed an interconnected cell layer on the bottom edge of the collagen
gel confirmed by platelet and endothelial cell adhesion molecule - 1 (PECAM-1)
expression. Immune cells can be directly injected into the channel on endothelial side.
Mucus and bacteria can be injected into the Y-shaped inlets. Cell viability and
differentiation can be quantified using fluorescent confocal microscopy and flow
cytometry.

The microfluidic mucosal barrier model provides a high throughput platform to test
hypothesis related to efficacy and immune compatibility of probiotics and therapeutics.
Simple chip design allows for real time monitoring of multiple species of bacteria cocultured with human derived epithelial and endothelial cells. Continuously replenishing
luminal content and the mucus gel layer can enhance the physiological relevance of this
model. Additional work is needed to confirm the sealed epithelial cell layer formation. Cell
seeding for epithelial, immune, and endothelial cells also needs to be adjusted to reflect the
physiological structure of the intestines. Different methods will be required to quantify the
permeability of the epithelial cell barrier such as dye-based methods or advance methods
to measure trans-epithelial electrical resistance (TEER). We found that HT-29 cells start to
form 3D aggregates after long-term culture. Other cell lines such as Caco-2 can be tested
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for better results with cell coverage and forming a sealed epithelial barrier. Additionally,
methods can be explored for covalent cross-linking of the collagen gel with the bottom
glass slide and the top PDMS cover for preventing leakage on the edges for long-term
studies. Also, immune cells showed limited migration in the collagen gel at the
concentration of collagen tested. Therefore, further tuning the collagen gel to enable
immune cell activity will enhance the functionality and applicability of this device. Since
the thickness of the collagen cannot be reduced further due to technical reasons, more
advanced methods can be tested to achieve vascularization of the collagen gel by
endothelial cells. This will enable capturing the phenomena of immune cell trafficking
from the immune cell channel to the site of epithelial cell injury in the microfluidic
platform. The assembly of the microfluidic chip is such that the cells can be retrieved for
downstream analysis including flow cytometry, DNA, RNA, and protein quantification.
Secreted molecules such as cytokines and chemokines can be easily retrieved for
quantification by collecting and replacing the medium over time.
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Figure 5.7 Microfluidic platform to reconstitute the mucosal and immunological
function of the intestines. (A) Schematic of the physiological structure and the cells
present at the mucosal interface. Mucus layer, epithelial barrier and the cells of innate
immune cells are in constant communication with the intestinal microbiota. (B) A
microfluidic chip design to incorporate bacteria, mucus, epithelial, and immune cells in a
physiological manner. (C) A microfluidic chip design that incorporates an additional
channel for adding endothelial cell layer with the cells of intestinal mucosa.
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Figure 5.8 Fabrication of the microfluidic platform containing the collagen gel for
supporting epithelial cell layer and embedded immune cells. (A) Schematic of the steps
involved in the fabrication of the microfluidic chip. (B) A key step in the fabrication
process is the manual addition of the collagen solution, and careful removal of the thin
PDMS piece from the central channel. The planar design enables real-time imaging of the
interactions occurring in the device.
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Figure 5.9 Testing the stability of the collagen gel and quantifying diffusion across the
gel layer. (A) Brightfield microscope image shows a stable collagen gel layer formed in
the rectangular region. The luminal channel is accessible to inlet and outlet flow. (B)
Fluorescent microscope images showing the diffusion of two different sizes of dextran
molecules. The rate of molecular diffusion was quantified by measuring the fluorescence
intensity over time showing that diffusion was dependent on the size of the molecules
tested.
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Figure 5.10 Testing viability of embedded immune cells and coculture with live
bacteria. (A) Fluorescent microscope image of THP-1 cells embedded in the collagen and
stained with blue live cell tracker. (B) RFP expressing E. coli Nissle 1917 cocultured with
embedded THP-1 cells. Bacteria growth and interaction with the immune cells was
captured over time.
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Figure 5.11 Demonstrating epithelial and mucus layer formation and coculture with
live bacteria. (A) Brightfield microscope image of the microfluidic device showing the
HT-29 epithelial cell layer covering the entire surface of the collagen gel. (B) High
magnification image shows 3D growth of epithelial cells and the fluorescent microscope
image shows the formation of epithelial cell junctions (EPCAM-1). (C) Fluorescent
microscope images show the maintenance of steady state by flowing the mucus layer and
the luminal content at equal flow rate of 3 μl/min. Presence of 20 mM Ca2+ in the luminal
content enable the formation of a distinct interface separating the bacteria (GFP S.
typhimurium) and the mucus layer. The underlying epithelial layer (blue) is prevented from
bacterial infection. Disrupting the flow of mucus caused infiltration of bacteria into the
mucus layer and epithelial cell infection.
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Figure 5.12 Demonstrating epithelial and endothelial layer formation in a single
microfluidic device. (A) Brightfield microscope image showing the collagen gel
separating the epithelial (Top) and the endothelial (Bottom) channels. (B) High
magnification images showing the formation of uniform epithelial (HT-29) and endothelial
(HUVEC) cell layers after three days of culture. Immunostaining of the fixed cells show
that epithelial cells expressed EPCAM-1 (Red) and the endothelial cells expressed
PECAM-1 (Green) indicating the formation of cellular junctions.
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5.5 Incorporation of primary gut organoids and immune cells for ‘Personalized
Medicine’ applications
Primary stem cell-derived organoids contain all the different types of cells present in the
epithelial cell layer in vivo including absorptive enterocytes, mucus secreting goblet cells,
Paneth cells, enteroendocrine cells, and microfold cells. Presence of these cell types enable
testing of specific hypotheses in vitro depending on the specialized function of the
respective cell type. The discovery of stem cell marker Lgr5 and commercial technology
development in the recent times have simplified the extraction of stem cells from freshly
excised tissues and the growth of these stem cells into three-dimensional (3D) organoids
(Figure 5.13A). These organoids are grown embedded in the extracellular matrix (ECM)
like Matrigel and form an enclosed structure with the lumen on the inside of the 3D
structure that is difficult to access for stimulation (Figure 5.13B). However, these organoids
can be dissociated to into single cells and re-seeded in commonly used platforms including
transwells, ECM derived scaffolds, and microfluidic platforms. This way in vivo like
epithelial monolayers can be formed that are accessible on both apical and basolateral sides
for drug discovery, studying transport or molecular secretion from the cells after
stimulation. To develop personalized models, the methods for recreating the mucosal
barrier presented in the thesis using immortal cell line for epithelial barrier can be easily
replaced with the primary epithelial cells derived from stem cell organoids (Figure 5.13B).
Additionally, the immortalized cell lines can be replaced by peripheral blood derived
mononuclear cells (PBMCs). PBMCs constitute a diverse population of the immune cells
that represent the effector cells during an immune response to immunomodulatory
molecules or infectious agents like bacteria, viruses, fungi, and parasites present in the
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lumen of the intestines. By donor matching the epithelial and immune cells in the in vitro
platforms described in this thesis can serve as personalized models for real time testing of
the efficacy and safety of probiotic bacteria and the fecal microbiota transplant (FMT) in
the treatment of gastro-intestinal disorders.
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Figure 5.13 Intestinal stem cell isolation and growth into 3D organoids. (A) Small
intestines excised from transgenic mice expressing red fluorescent protein variant (DsRedExpress) under the direction of the mouse doublecortin (Dcx) promoter using a commercial
isolation kit and protocol (Stemcell Technologies Inc.). Cells are embedded in a dome of
Matrigel matrix. (B) 3D buds start to originate from individual stem cells after 1 day of
culture. After 7 days of culture crypt and villous structure form with a lumen at the center
of the organoids that contain dead cell debris. (C) Schematic of a ‘single translational
platform’ for personalized models of human organs on a microfluidic chip.
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5.6 Overall conclusion
In the first part of the thesis, a high throughput method to extract natural mucus was
developed that will stimulate broad aspects of mucus barrier research. Using mucus
extracted with this process, we have shown that the local ionic environment plays an
important role in regulating the biophysical properties of the mucus barrier. Integration of
the extracted mucus with an epithelial cell layer lead to the development of the mucosal
barrier model of the intestines in vitro. Using the mucosal barrier model, we demonstrated
the role of flagellar motility in promoting bacterial infection and inducing proinflammatory cytokine and chemokine production from epithelial and immune cells.
Mucosal barrier model was further used to elucidate that depending on the dosage,
probiotics can be beneficial against pathogenic infection, but insufficient dosage and
presence of mucus induce hypervirulence in S. typhimurium and higher inflammatory
response. Finally, advanced applications of the mucus biomaterial in developing
translational platforms ranging from therapeutic delivery to micro-physiological models
using microfluidics have been described. The techniques presented here will help uncover
the mechanisms behind the effects of environmental molecules on biophysical properties
of mucus. The in vitro mucus barrier model is functional and can be tuned to match
physiological thicknesses and densities like native mucus. We envision that these models
will serve as high throughput tools for understanding the role of mucus barrier in nutrient
absorption, host-microbiome interactions, and drug absorption. A better understanding of
mucosal barriers and their interaction with the local environment has potential to improve
treatment of intestinal diseases and other mucosal barrier organs.
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ADDITIONAL FIGURES

Figure 2.S1. Quantification and removal of total DNA post PSIM extraction. Change
in total DNA after DNAse treatment of PSIM at room temperature for 10 hours compared
to the untreated PSIM.
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Figure 2.S2. Theoretical quantification of total mucus on the luminal surface of the
pig intestines. Schematic representation of gross small intestinal (SI) morphology and
microstructure showing the components that contribute to increase in the surface area of
the small intestine. In the equation for mucus amount, π (Ro2 –Ri2) is the cross-sectional
surface area of a hollow cylinder, and plicae circularis and villi structures increased the
cross-sectional area by factors of 3 and 7.55, respectively. The theoretical amount of mucus
per meter length was based on an outer radius (Ro) of 12.5 mm, an inner radius (Ri) of
12.45 mm, and pig small intestinal mucus concentration of 20 mg/ml.
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Figure 2.S3. Absorbance spectra of 2 % (w/v) PSIM in the pH range 2-7. Data was
plotted as an average of three independent intestine samples from different pigs.
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Figure 2.S4. Rheological data for the change in dynamic moduli (G՛ and G՛՛) of PSIM
(2% w/v). The measurements were performed in the frequency range 1-68.3rad/s at 37oC
(N = 3 PSI).
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Figure 2.S5. Gross image of PSIM compared to Porcine gastric mucin (Type II, Sigma
Aldrich). The freeze-dried samples were solubilized in 20mM HEPES solution at a
concentration of 8% (w/v), and at values of 7 and 4 respectively.
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Figure 3.S1. Mucus layer thickness is concentration dependent. (A) Brightfield
micrographs of histological sections with epithelial layer (black border arrows) and mucus
layer (white arrows). (B) Mucus layer thickness increased with PSIM concentration.
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